Introduction {#s1}
============

Environmental rigidity affects cell morphogenesis and development. For example, mesenchymal cells develop long protrusions and spread when they are cultured on glass coverslips or plastic plates ([@bib46]), but fail to do so on soft substrates (*E* \< 5 kPa) in cell culture. Likewise, rigid substrates (*E* \> 20 kPa) facilitate differentiation of mesenchymal stem cells into osteogenic cells ([@bib24]). In fact, the behavior of mesenchymal cells reflects the response of most migratory/adherent cells. By contrast, newborn neurons, which naturally reside in extremely soft tissue environments (*E* = 0.1--1 kPa) such as brain ([@bib10]; [@bib31]), behave differently. Soft mechanical properties generally favor neuronal differentiation ([@bib24]; [@bib64]) and maturation ([@bib4]; [@bib25]; [@bib44]). In particular, neurons extend long protrusions known as neurites toward softer surfaces when cultured on substrates showing a stiffness gradient ([@bib68]). In vivo evidence for the inverse durotaxis of neuronal cells has been provided recently using retinal ganglion cells of *Xenopus* embryos, which exhibited a noticeable pattern of stiffness gradients within the optic tracts toward their targets in the optic tectum ([@bib42]). Such distinct behavior plays a crucial role in establishing projections and dendritic territory. Although transduction mechanisms governing the development and behavior of migratory cells on rigid substrates in cell culture are well characterized ([@bib3]; [@bib21]), mechanisms underlying how neurons behave differently from migratory cells on soft substrates remain elusive.

In general, development of cell shape depends on coordination of dynamic membrane activities such as endocytosis, exocytosis, or adhesion with cytoskeletal mechanics. For adherent cells grown on matrices, development of cell shape primarily relies on integrin-mediated adhesions, which recruit molecules such as paxillin and vinculin ([@bib20]; [@bib39]; [@bib66]; [@bib73]) to adhesive anchorages and to generate tensile forces ([@bib8]; [@bib16]). The morphogenetic differences between neurons and migratory cells in soft environments suggest that mechanisms other than integrin-mediated adhesion may function in neurite initiation. Potential candidates are changes in the gene expression and cell signaling that govern endocytosis, which functions not only in membrane dynamics but also in integrin internalization and focal adhesion disassembly ([@bib9]; [@bib19]; [@bib40]; [@bib53]; [@bib74]). Furthermore, endocytosis is required to activate and recruit the neuritogenic signal molecule Rac1 ([@bib55]) to the membrane, an activity that enhances formation of cell protrusions through actin filament polymerization ([@bib36]; [@bib48]; [@bib49]).

Neurite initiation is the very first step of a single neuron toward neuronal networking. To fully appreciate the role of soft environments in neuronal development, ranging from cell fate to cell shape, it is challenging but vital to determine the underlying mechanism responsible for the spatiotemporal control of neurite initiation in the embryonic brain. To investigate mechanisms driving neurite initiation in soft tissue environments, we cultured embryonic rat primary hippocampal neurons on hydrogels of various elastic moduli and monitored spatiotemporal patterns of neurite initiation and corresponding changes in gene expression. We observed a bistable pattern of neurite initiation associated with altered expression of genes encoding components of the endocytic machinery. In the absence of neurite-promoting factors, endocytosis was required for cells to form the morphological precursors of neurites, that is, segmented lamellipodia. We identified paxillin as a key protein that directly associates with either the adhesion protein vinculin or the F-BAR-containing endocytic factor CIP4. When grown on soft substrates, cells expressed high levels of paxillin associated with the endocytic machinery, which in turn upregulated Rac1 activity to promote neurite formation and elevate expression of proteins of the endocytic machinery as part of a positive feedback loop. By contrast, cells grown on rigid substrates developed numerous adhesions, which sequestered paxillin from the endocytic machinery and delayed neurite initiation. Using genetic profiling and biochemical approaches, we show that paxillin-mediated endocytosis and formation of adhesions constitute a bistable switch to control neurite initiation in a substrate modulus-dependent manner.

Results {#s2}
=======

Bistable substrate modulus-dependent behavior in neurite initiation {#s2-1}
-------------------------------------------------------------------

We used polymerized hydrogels to define the mechanisms underlying neurite initiation in soft environments. Gels of three elastic moduli---0.1, 1 and 20 kPa---were engineered and verified by atomic force microscopy (see Materials and methods, and [Figure 1---figure supplement 1A--D](#fig1s1){ref-type="fig"}). Culturing hippocampal cells isolated from embryonic day 17.5 (E17.5) rat brain on these compliant gels can selectively enrich the population of neurons by up to 80% and minimize growth of glial cells ([Figure 1---figure supplement 1E](#fig1s1){ref-type="fig"}). After seeding cells onto gels and incubating them for either 5 or 16 hr in regular neurobasal medium, we assessed potential morphogenetic changes in cells over time. Upon initial gel contact, cells formed a uniform lamellipodial extension ([Figure 1A1](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2A,B](#fig1s2){ref-type="fig"}), which became segmented into multiple, separated lamellipodia if the gel was sufficiently soft (see [Figure 1---figure supplement 2A--D](#fig1s2){ref-type="fig"}). Lamellipodia are well-known morphological precursors of neurites ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}; [@bib15]). However, we observed that neurites formed only if their preceding lamellipodia occupied less than a third of the entire cell periphery; lamellipodia occupying \>1/3 of the periphery failed to form neurites even at the 16 hr time-point ([Figure 1A2--A4](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2A--D](#fig1s2){ref-type="fig"}). Therefore, we defined each lamellipodium with \<1/3 occupancy of the entire cell periphery as a 'segmented' lamellipodium (SL), and those occupying \>1/3 as a 'broad' lamellipodium (BL). In most, if not all, cases of the 5 hr cultures, a single cell could not have both SL and BL.

![Morphology and endocytic activity of neurons grown on substrates of varying stiffness.\
(**A**) Substrate modulus-dependent biphasic distribution of lamellipodium occupancy. (**A1**) Representative intensity profile of phalloidin-stained hippocampal neurons on a soft hydrogel (*E* = 0.1 kPa). Lamellipodium occupancy (LO) of each phalloidin-positive segment is calculated by the formula shown in the box at bottom right. (**A2**) Representative images of neurons grown on substrates for 5 hr or 16 hr and stained with phalloidin (Red), DAPI (Blue), and antibodies against Tuj-1 (Green), as indicated. Scale bar: 20 μm. (**A3**) Histograms of LO distributions at 5 hr showing two distinct patterns in 0.1, 1, or 20 kPa cultures (n \> 68 cells for each experiment). Simplified drawings above histograms illustrate the typical segmented lamellipodium ('SL') and broad lamellipodium ('BL') phenotypes in 5 hr neuronal cultures, as indicated. (**A4 and A5**) Histograms summarizing the percentages of lamellipodium phenotypes seen in 5 hr cultures (**A4**) and the distributions of neurite numbers (**A5**) in 16 hr cultures. Data represent mean ±SEM (n \> 3 independent experiments; 150 cells for each culture; \*p\<0.05; \*\*p\<0.01; \*\*\*\*p\<0.0001; one way ANOVA with *Dunnett's post hoc* test). (**B**) Enhanced membrane endocytosis in 0.1 kPa cultures. Time-lapse images (20 frames; 2 min intervals) of neurons isolated from E17.5 rat cortices transfected in utero at E16 without (**B1**) or with (**B2**) IRES constructs harboring control EGFP and/or a dominant-negative dynamin II mutant (DynII^K44A^), cultured on 0.1 kPa or 20 kPa gels for 5 hr, followed by endocytosis assay in the presence or absence of the endocytosis inhibitors Dynole 2--24 or Dyngo 4a, as indicated. Dashed lines surround the region of interest (ROI) in quantitative FM4-64 measurements. Asterisks in B2 mark non-transduced neighboring cells. Graph at right summarizes the accumulation curves of FM4-64 signal (±SEM, n \> 3 independent experiments, 10--20 cells per group, normalized to *t* = 0 value; \*\*\*\*p\<0.0001; two-way RM ANOVA with *Dunnett's post hoc* test), which reflects the rate of FM4-64 uptake at different time-points after FM4-64 loading. The data were fitted to a single exponential to determine the time (*t*~1/2~) required to reach half of the plateau value. (**B3**) Representative images of neurons plated on 0.1 kPa or 20 kPa gels overnight, followed by incubation of quantum dot-conjugated brain-derived neurotrophic factor (QD-BDNF) for 5 hr. Dot plot showing that 0.1 kPa cultures exhibited a significantly higher level (n = 39--46 cells from three independent experiments; \*\*p\<0.001; \*\*\*\*p\<0.0001; one-way ANOVA with *Dunnett's post hoc* test) of QD-BDNF internalization (as reflected by a \~2-fold greater quantity of intracellular QD-BDNF) than 20 kPa cultures. (**C**) Expression of DynII^K44A^ prevents neurite formation and cortical neuron migration in vivo. (**C1**) Fluorescence images of P0 rat cortices transfected in utero at E16 with IRES constructs harboring control EGFP and/or DynII^K44A^. The middle panels show 16x magnifications of boxed regions of the corresponding P0 cortex in the top panels. The bottom panels show sample tracings of 2D projections from confocal images of typical cortical neurons in the corresponding P0 cortex. Bar, 100 μm. (**C2 and C3**) Histograms showing the localization (**C2**) and the percentage (**C3**) of transfected cortical neurons exhibiting unipolar/bipolar polarized processes ('polarized'), multiple short neurites without a long tailing process ('unpolarized'), or no process ('no neurite'; arrowheads in the middle panels) in the cortical plate ('CP') or subventricular zone/intermediate zone ('SVZ/IZ') regions. Datasets (mean ±SEM, n \> 150 cells per cortex, \>5 cortices each; \*\*\*p\<0.001, multiple *t* test) showing significant differences are marked.](elife-31101-fig1){#fig1}

We identified a bistable substrate modulus-dependent behavior by measuring the distribution of SL and BL over various substrates of varying stiffness ([Figure 1A3](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2E,F](#fig1s2){ref-type="fig"}). Cells could be segregated into two populations, that is, those with or without SL formation, in a substrate modulus-dependent manner. For example, in 5-hr soft-gel cultures (0.1 kPa), nearly 100% of cells formed SL ([Figure 1A4, A5](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}), whereas most cells (\~71.5%) on stiff-gel cultures (*E* = 20 kPa) or coverslips (glass) failed to form SL and instead formed a single BL ([Figure 1A4](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2E,F](#fig1s2){ref-type="fig"}). In 16 hr cultures, the SL of most (\~98%) cells on soft gels had become neurites, whereas more than half (\~57.3%) of the cells on stiff gels possessed BL and lacked neurites ([Figure 1A5](#fig1){ref-type="fig"}). Such bistable behavior suggests the existence of two distinct states in early stages of neuritogenesis; a 'segmentable state' in which cells can form segmented lamellipodia as morphological predecessors of neurites, and a 'non-segmentable state' in which cells retain a spreading morphology with broad lamellipodia. The fact that cells form neurites on soft gels in the absence of neurite-promoting growth factors suggests that culturing cells on environments with elastic moduli \<1 kPa, which match the mechanical properties of brain (*E* = 0.1---1 kPa; ([@bib10]; [@bib31]), is sufficient to initiate neurite formation. Moreover, surface laminin was detectable on 0.1 kPa, 20 kPa and glass surfaces, and it was comparable following 5 and 16 hr incubation periods in neuronal culture media (see [Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}), ruling out a difference due to coating. Note that when culturing cells on coverslips, lower laminin/PLL concentrations may be required for proper laminin/integrin interaction to overcome the influences of high substrate rigidity (please see [Appendix 1---figure 1](#app1fig1){ref-type="fig"}).

Substrate modulus-dependent morphogenesis is associated with distinct cell signaling and gene expression patterns {#s2-2}
-----------------------------------------------------------------------------------------------------------------

To ascertain whether changes in gene expression are associated with segmentable or non-segmentable states, we undertook genetic profiling of cells grown on soft or stiff substrates at 5 or 16 hr time-points. Using mRNA microarray and Gene Ontology analyses, we identified 114 differentially expressed mRNA transcripts in cells grown on 0.1 kPa and 20 kPa gels at the 5 hr time-point (filtering criteria: fold change ≥1.5, p\<0.05; [Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}, and [Appendix 1---table 1](#app1table1){ref-type="table"}, [2](#app1table2){ref-type="table"}). Among them, 66 were upregulated in 0.1 kPa gel cultures and the remainder were downregulated (compared to cells grown on stiffer substrates). Notably, three genes---*Cltc, Dab2*, and *Myo6*, all of which function in clathrin-mediated endocytosis---were co-upregulated in 0.1 kPa gel cultures at the 5 hr time-point ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}), suggesting that cells enter a high endocytic state on a soft substrate (*E* = 0.1 kPa). By contrast, several adhesion factors, including *Vcl*, *Nrcam*, *Robo2* and *Cdh11*, were relatively upregulated in 20 kPa gel cultures at 5 hr and/or 16 hr compared to cells grown on softer substrates ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}).

To verify that changes in gene expression associated with endocytosis or adhesion were correlated with phenotypic changes, we performed single molecular RNA fluorescent in situ hybridization (smFISH, see Materials and methods for details), which enables mRNA quantitation in two groups of single cells based on their morphological signatures, that is, BL or SL ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). For this analysis, we examined nine genes involved in three different types of cellular activities: endocytosis, adhesion, and the Hippo-YAP pathway. All these pathways regulate membrane mechanics under certain conditions. In 5 hr cultures, we found that SL cells expressed relatively lower (2.3- to 10-fold) and higher (1.2- to 4-fold) levels of adhesion-related (*Vcl, Cdh11 and Robo2*) and endocytic (*Cltc, Dab2*, and *Myo6*) mRNA, respectively, compared to those of BL cells ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). However, no significant differences were observed in levels of the Hippo-YAP-related (*DKK1* and *CYR61*) mRNA between SL and BL cells. Although fold-changes in gene expression vary across signal detection methods ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}), these findings are consistent with the microarray data and suggest that cells with segmented lamellipodia undergo preferential gene expression of endocytic- but not adhesion-related genes.

Elevated endocytic activity is associated with soft substrate environments and is critical for neurite development in vivo {#s2-3}
--------------------------------------------------------------------------------------------------------------------------

To ascertain whether neurons enter an endocytic-dominant state upon contact with soft environments, we measured endocytic activity in cells grown on soft or stiff gels. To assess endocytosis, first we monitored uptake of the lipophilic dye FM4-64 over a 40 min period (at 2 min intervals) in 5 hr cultures ([Figure 1B1](#fig1){ref-type="fig"}). The rate of FM4-64 uptake was reflected by the time required to reach half of the maximum FM4-64 intensity measured in cells, defined as *t*~½~. We observed that cells grown on 0.1 kPa gels exhibited a \~1.6-fold greater FM4-64 intensity at the end-point of the measurements (t = 40 min), and a \~1.7-fold greater uptake rate \[*t*~½\ (0.1\ kPa)~ v.s. *t*~½\ (20\ kPa)~=16.8 min v.s. 24.8 min\] than cells grown on 20 kPa gels ([Figure 1B1](#fig1){ref-type="fig"}). Robust dye uptake was pharmacologically and genetically abolished by applying inhibitors of dynamin GTPase and by ectopically expressing a dominant-negative Dynamin II mutant (DynII^K44A^; ([@bib14]; [@bib37]) in 0.1 kPa cultures, respectively ([Figure 1B1, B2](#fig1){ref-type="fig"}). These results suggest that dye uptake is primarily endocytosis-associated. Note that constructs encoding DynII^K44A^ were in utero eletroporated (IUE, ([@bib65]) into the developing brain of E16 rat embryos. Cultures were prepared 24 hr after electroporation to allow for sufficient expression of DynII^K44A^. To confirm that levels of legend-mediated endocytosis were elevated in neurons grown on soft substrates, we then quantified invagination of quantum dot-conjugated brain-derived neurotrophic factor (denoted as QD-BDNF and exhibiting a 1:1 BDNF:QD conjugation ratio; see Materials and methods) in 16 hr cultures ([Figure 1B3](#fig1){ref-type="fig"}). We observed an average invagination rate of \~7 dots per cell in 0.1 kPa cultures over the first 5 hr after bath application of QD-BDNF. That rate was significantly decreased to two dots per cell in 20 kPa cultures ([Figure 1B3](#fig1){ref-type="fig"}), and comparable results were seen following dynamin inhibition ([Figure 1B2](#fig1){ref-type="fig"}). These findings suggest that cells grown on soft substrates undergo a high level of endocytosis.

These findings prompted us to examine the functional relevance of endocytic activity on neurite formation in vivo. To do so, we used in utero electroporation to express constructs encoding a dominant-negative Dynamin II mutant (DynII^K44A^) in a subpopulation of neural progenitor cells ([Figure 1C](#fig1){ref-type="fig"}). To aid observations of morphogenetic phenotypes, brain slices were obtained from newborn (P0) rat cortex when most newly differentiated neurons had extended their neurites and migrated towards the cortical plate. Nearly all (\~100%) control cortical neurons (i.e. those solely expressing marker protein) exhibited a neurite-bearing, polarized morphology ([Figure 1C1, C3](#fig1){ref-type="fig"}), with dendritic arbors being oriented toward the pial surface and the axon being oriented radially in the cortical plate. By contrast, cortical neurons expressing DynII^K44A^ exhibited an apparent migration defect ([Figure 1C1, C2](#fig1){ref-type="fig"}), with a high percentage of cells having a non-polarized morphology without extension of minor processes (termed 'no neurite') and a reduced percentage of cells exhibiting a polarized morphology (unipolar or bipolar) ([Figure 1C3](#fig1){ref-type="fig"}). Thus, a normal level of endocytic reactions is required for proper neurite formation and radial migration of newly generated cortical neurons; two tightly linked events during neuronal development in vivo.

The endocytic-dominant state on soft substrates favors Rac1 signaling and neurite formation {#s2-4}
-------------------------------------------------------------------------------------------

Endocytosis enhances membrane translocation and Rac1 activation ([@bib55]) and, although in opposing manners, both RhoA and Rac1 function in neurite formation ([@bib2]; [@bib13]; [@bib33]; [@bib47]); reviewed in [@bib35]). Given the dominance of endocytosis events on soft gels, we wondered whether the substrate modulus governed Rac1 activity. Using an active Rac1 pulldown assay, immunofluorescent staining of Rac1 or active Rac1, and the FRET biosensor Rac1-2G ([@bib28]; [@bib29]), we observed that, unlike RhoA, Rac1 activity decreased with increasing stiffness of the substrate in 5 hr neuronal cultures ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). In addition, active Rac1 accumulated in SL and the tips of growing neurites, whereas there was no accumulation in BL ([Figure 2A1, A3](#fig2){ref-type="fig"}). Consistently, ratiometric FRET imaging confirmed accumulation of active Rac1 at segmented neuronal lamellipodia on soft gels (0.1 kPa), with FRET signal decreasing from the leading edge to the cell body ([Figure 2B1, B2](#fig2){ref-type="fig"}). Moreover, either expression of DynII^K44A^ or treatment of the 0.1 kPa cultures with inhibitors of endocytosis significantly blocked accumulation of active Rac1 ([Figure 2A1--A3](#fig2){ref-type="fig"}). These results suggest that Rac1 accumulation requires endocytosis.

![Substrate modulus-dependent Rac1 increase and lamellipodium segmentation require endocytic activity.\
(**A**) Inhibition of endocytosis suppresses Rac1 activity in 0.1 kPa cultures. (**A1--A3**) Representative images of 5 hr neuronal cultures treated with the endocytosis inhibitors dynasore (50 μM, 1 hr), Dynole 2--24 (2--24, 2 μM, 1 hr), Dyngo 4a (4a, 2 μM, 1 hr) or monodansylcadaverine (MDC, 100 μM, 1 hr) and immunostained with antibodies against Rac1, GTP-bound Rac1 ('active Rac1'; A1, left panel), or RhoA (A1, right panel). The same staining procedure was applied to the IUE neuron (A2, arrow) expressing control EGFP and/or DynII^K44A^ as shown in A2. Asterisks mark non-transduced neighboring cells. Intensities of active Rac1 and RhoA correspond to linear pseudocolor maps. (**A3**) Histograms, all from experiments similar to those described above, showing that endocytosis inhibition significantly decreases levels of total Rac1 and active Rac1 (but not RhoA) at lamellipodial protrusions (at 5 hr) in 0.1 kPa cultures. Data represent mean intensity ±SEM (n \> 50 per group from three independent experiments; \*\*\*p\<0.001; one-way ANOVA with *Dunnett's post hoc* test). (**B**) Representative FRET-based imaging of hippocampal neurons transfected with a FRET indicator for GTP-bound Rac1 (Rac1-2G; see Materials and methods). (**B1**) Images of monomeric Teal fluorescent protein 1 (mTFP1) and FRET signals (presented as pseudocolor maps in a linear scale) acquired from neurons plated on 0.1 kPa gels in the presence or absence of dynasore (50 μM) or MDC (100 μM) for 1 hr. Bar, 20 μm. (**B2**) Traces depict active Rac1 levels at protrusions, measured across the dashed line as shown in **B1**, and indicated by FRET signal calculated as the ratio of Venus to mTFP1 fluorescence \[F(Venus)/F(mTFP1)\]. (**B3**) Quantitative measurement of FRET signals (±SEM, n = 5 cells for each group; \*p\<0.05, compared to time = 0 value; multiple *t* tests) before and after bath application of 50 μM dynasore or 100 μM MDC. Arrow marks drug addition (time = 0). (**C**) Inhibition of endocytosis decreases the probability of lamellipodium segmentation and delays neurite initiation on soft gels. (**C1**) Representative fluorescent images of neurons plated on 0.1 kPa gels for 5 hr in the absence or presence of indicated endocytosis inhibitors. Scale bar: 20 μm. (**C2**) Representative fluorescent images of transfected IUE neurons (arrow) expressing control EGFP and/or a dominant-negative dynamin II mutant (DynII^K44A^), cultured on 0.1 kPa gels for 16 hr, and stained with phalloidin (Red), DAPI (Blue), and antibodies against Tuj-1 (Green). Asterisks mark non-transduced neighboring cells. Scale bar: 20 μm. Histograms summarize the percentages (±SEM; \*\*\*p\<0.001, one way ANOVA with *Dunnett's post hoc* test) of 16 hr neurons bearing neurites in the presence or absence of dynasore (50 μM, 5 hr treatment) or MDC (100 μM, 5 hr treatment), as indicated.](elife-31101-fig2){#fig2}

Previous studies have shown that Rac1 activation induces cell protrusions through actin filament polymerization (reviewed in \[[@bib36]; [@bib61]\]). To ascertain whether Rac1 increase and accumulation on soft gels (0.1 kPa) was responsible for neurite initiation, we treated cells grown on soft gels with the Rac1 inhibitor NSC 23766 immediately after plating and assessed phenotypes at the 5 hr time-point, which resulted in the onset of lamellipodial segmentation being significantly delayed (see 48 hr time-point in [Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In support of the idea that Rac1 accumulation requires endocytosis ([Figure 2A](#fig2){ref-type="fig"}), inhibition of endocytosis in soft-gel cultures for 1 hr also significantly increased manifestation of the BL phenotype at the 5 hr time-point ([Figure 2C1](#fig2){ref-type="fig"}), with \>90% of cells exhibiting sparsely distributed and less activated Rac1 and broad lamellipodia that resembled those seen on 20 kPa gels ([Figure 2A,B](#fig2){ref-type="fig"}). The number of neurite-bearing neurons was also decreased to \~13% compared to the untreated control ([Figure 2C2](#fig2){ref-type="fig"}). In contrast, bath-application of Y27632 (an inhibitor of Rho-associated protein kinase, ROCK) or the PI3k inhibitor LY294002 to 0.1 kPa cultures did not alter the onset of lamellipodial segmentation ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). These results suggest that culturing cells on a soft substrate is sufficient to promote a neuritogenic state through endocytosis-associated Rac1 activation.

Model for competitive recruitment of paxillin to divergent cellular machineries as part of a bistable switch {#s2-5}
------------------------------------------------------------------------------------------------------------

In many biological systems, selection between two distinguishable states requires changes in gene expression, which are then amplified via a bistable switch (reviewed in \[[@bib26]; [@bib67]\]). Our results suggest that newborn neurons possess two morphological states: one with the ability to form segments and neurites and the other without. These states are associated with specific genetic changes that are governed by substrate stiffness, cell contractility, and endocytic activity ([Figure 1](#fig1){ref-type="fig"} and [Figure 2](#fig2){ref-type="fig"}). To account for both endocytosis and adhesion, here we assume a simple 'sequestering' mechanism whereby a factor/switcher required for both endocytosis and cell-substrate adhesion exists (mathematical model and figure shown in Appendix). To identify the molecular switch, we evaluated by western blot analysis the protein levels of candidate molecules functioning in adhesion or the endocytosis machinery. In 5 hr cultures on stiff substrates (20 kPa gels or glass), cells expressed higher levels of adhesion factors (such as integrin β1; for the level of active integrin, please see [Appendix 1---figure 3](#app1fig3){ref-type="fig"}) than endocytic factors ([Figure 3A,B](#fig3){ref-type="fig"}). Although pFAK levels increased slightly on stiff substrates, the changes were not statistically significant. By contrast, cells grown on soft gels (0.1 kPa and 1 kPa) expressed higher levels of factors associated with clathrin-mediated endocytosis, including myosin VI, clathrin heavy chain (CHC) and Cdc42 interacting protein 4 (CIP4) ([Figure 3A,B](#fig3){ref-type="fig"}). Among the candidates of interest, we also evaluated the scaffolding protein paxillin, which is known to be an integral component of focal adhesions that bind vinculin and FAK ([@bib66]; [@bib72]). We observed that expression levels of paxillin and phosphorylated paxillin in cultured neurons did not match the profiles of other adhesion factors, but instead matched the profiles of endocytic factors ([Figure 3A and B](#fig3){ref-type="fig"}). Further analysis of relative paxillin expression in 5 hr cultures indicated that cells grown on soft substrates (0.1 kPa gels) expressed significantly higher levels of paxillin than those grown on stiff substrates ([Figure 3B](#fig3){ref-type="fig"}). These observations strongly suggest that paxillin is associated with the endocytic machinery in soft cultures and may serve as the proposed switcher.

![Substrate modulus-dependent expression of paxillin and its association with endocytic and adhesion machineries.\
(**A**) Representative western blots of endocytic or adhesion molecules. Cell lysates obtained from cortical neurons grown on substrates with differing stiffness were subjected to immunoblotting with antibodies to indicated proteins. (**B**) Summary histograms, all from experiments similar to that described in **A**, showing greater (\>2 fold) abundance of paxillin, phospho-paxillin^Y118^ (p-paxillin), myosin VI (myo6), CIP4 and clathrin heavy chain (CHC) proteins in neurons grown on soft substrates (0.1 and 1 kPa) compared to those grown on stiff substrates (20 kPa and glass). Note the inverse expression of endocytic factors and adhesion molecules (i.e., talin1/2, integrinβ1, vinculin and p-FAK^Y397^). Data represent mean ±SEM (n ≥ 3, normalized to control actin; compared to 0.1 kPa cultures; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; *t*-test). (**C--F**) Paxillin co-localizes with the endocytosis complex at neuronal growth cones on soft substrates. (**C**) Representative confocal images of 16 hr neurons on 0.1 kPa gels co-immunostained with antibodies against paxillin (Green in merge panel), adaptor-associated kinase1 (AAK1, Red in merge panel), p-FAK^Y397^ (Red in merge panel), or F-actin, as indicated. Right panels show the region of interest ROI (marked by numbers) of neurite tips represented at higher magnification. Bar: 20 μm. (**D and E**) Similar to **C**, except the resolution of images has been enhanced (\~1.7X higher) using Airyscan. Note that surface rendering was applied at neurite tips to more clearly show co-localization (yellow) of paxillin with indicated factors. Bar: 20 μm. (**F**) Histograms, all from experiments similar to those described in **d** and **e**, summarizing percentages of paxillin co-localized with indicated endocytic or adhesion factors on hydrogels. Data represent percentages (±SEM, n = 15 neurons for each set of experiments; ROI, 5 × 5 µm within one lamellipodium; \*\*p\<0.01; \*\*\*p\<0.001; \*\*\*\*p\<0.0001; *t* test).](elife-31101-fig3){#fig3}

Evidence for a role of paxillin in endocytosis is limited (but see \[[@bib22]\]). To examine this possibility, we assessed if paxillin is associated with endocytic vesicles using a detergent-free membrane flotation assay of embryonic rat cortex (with cardiac tissue used for comparison). We found \>30% of paxillin from brain lysates co-fractionated with the endocytosis factors Rab5 and CHC (in floating membrane fractions), whereas co-fractionation was \<5% in cardiac lysates ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), suggesting that a significant proportion of paxillin is associated with endocytic vesicles in neurons. Live cell imaging also revealed a long-range, predominantly retrograde transport of paxillin-mCherry from axonal tips ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 3---video 1](#fig3video1){ref-type="video"}); a behavior similar to that seen in neuronal signaling endosomes ([@bib12]; [@bib79]). Next, we wondered whether paxillin preferentially binds to endocytic rather than adhesion factors in the segmentable state. Using 5 hr soft-gel cultures, we conducted immunostaining of endocytosis-associated kinase AAK1 ([@bib11]; [@bib60]) or adhesion kinase p-FAK^Y397^. A significant proportion (\~39%) of paxillin staining colocalized with that of AAK1 rather than p-FAK^Y397^ on soft gels (0.1 kPa; [Figure 3C](#fig3){ref-type="fig"}). This outcome was quantitatively confirmed by confocal microscopy with enhanced resolution (\~1.7X greater using Airyscan). In cells exhibiting an SL phenotype on soft gels (0.1 kPa), enhanced resolution confocal microscopy also revealed that a significant portion (\>40%) of paxillin appeared in a punctate pattern and co-localized with the endocytic factors CHC or AAK1 (Pearson's coefficient \>0.75) rather than adhesion factors p-FAK^Y397^ or vinculin (Pearson's coefficient \<0.45) ([Figure 3D,F](#fig3){ref-type="fig"}). Interestingly, paxillin preferentially associated with p-FAK^Y397^ and vinculin in cells exhibiting BL on stiff gels (20 kPa; [Figure 3E,F](#fig3){ref-type="fig"}). Together, these observations suggest that paxillin functions in both endocytic and adhesion activities.

Endocytic factor CIP4 and adhesion factor vinculin are potential competitors for paxillin binding {#s2-6}
-------------------------------------------------------------------------------------------------

Validation of our model requires that a molecular switch binds to endocytic and adhesion machineries in a competitive and substrate modulus-dependent manner. To determine whether paxillin meets these criteria, we tested its binding to the endocytic machinery using liquid chromatography-tandem mass spectrometry (LC−MS/MS) of lysates from rat embryonic brain and in vivo co-immunoprecipitation of cortical neurons cultured on hydrogels. Our analyses identified several endocytic factors that bind to paxillin, including clathrin, dynamin, and CIP4 ([Figure 4A--C](#fig4){ref-type="fig"}, and [Appendix 1---table 3](#app1table3){ref-type="table"}). Moreover, the binding affinity of paxillin to these factors increased with substrate compliance, whereas the binding affinity of paxillin to vinculin increased with substrate stiffness ([Figure 4A](#fig4){ref-type="fig"}). These findings indicate that paxillin can switch its binding preference in a substrate modulus-dependent manner.

![The endocytic F-BAR protein CIP4 directly associates with paxillin and competes with vinculin for paxillin binding.\
(**A**) Paxillin preferentially binds endocytic factors in neurons grown on soft substrates. Paxillin-associated complexes were immunoprecipitated (IP) in lysates made from E17.5 rat brain or from cortical neuronal cultures grown on different substrates using a specific paxillin antibody and were then detected by western blot analysis. Normal rabbit IgG ('IgG') served as a negative control. Histograms show the opposing binding preference of paxillin toward CIP4/CHC or vinculin when grown on soft (0.1 kPa or 1 kPa) versus rigid (20 kPa or glass) substrates. Data represent mean intensity ±SEM (n = 3 independent experiments; \*p\<0.05; *t-*test). (**B**) Western blot showing direct interaction of paxillin with CIP4. Bacterially expressed His-CIP4 was purified by fast protein liquid chromatography and subjected to a GST pull-down assay using GST-PXN^FL^, GST-PXN^∆LIM3-4^ or GST alone. Precipitants were analyzed by western blotting with antibodies specific to CIP4. Histograms summarize protein levels as determined by immunoblotting of full-length (His-CIP4) or F-BAR domain-deleted (His-ΔF-BAR) CIP4 pulled-down by GST-paxillin variants (±SEM, n = 3; normalized to the corresponding GST-PXN^FL^ or GST-PXN^∆LIM3-4^ inputs; \*\*p\<0.01, *t* test). (**C** and **D**). Mapping of paxillin domains interacting with CIP4 or vinculin. (**C**) GST pull-down and immunoblotting of vinculin, myc-CIP4, and CHC in lysates of myc-CIP4-expressing HEK293T cells. Histograms reflect quantification of levels of proteins pulled-down by GST fusions of full-length ("FL") or LIM domain- and/or LD motif-deleted forms of paxillin, all from experiments similar to those shown in top panels (±SEM, n ≥ 3 independent experiments; \*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001; *t* test). (**D**) Schematic of GST fusion proteins used in **c**. Table summarizing relative CIP4 or vinculin ('Vin') binding by paxillin deletion mutants or full-length protein. Solid lines mark primary sites of interaction, and dashed lines mark accessory interaction motifs for strong binding to vinculin or CIP4. Binding strength relative to full-length paxillin indicated as: '++++\' \>75% \> '+++\' \>50% \> '++\' \>25% \> \'+\' \>5% \> \'+/-\'. (**E**) In vitro protein interaction and competitive binding assays in HEK293T cells transfected with various amounts (1, 6, and 12 µg) of plasmids encoding myc-tagged CIP4 protein (myc-CIP4) and/or control vectors, as indicated. Cell lysates were subjected to a GST pull-down assay with GST-PXN^FL^ or GST alone, and immunoblotted with vinculin and myc antibodies. Line chart depicts averaged protein levels as determined by immunoblotting of CIP4 or vinculin pulled-down by GST-PXN^FL^ (±SEM, n = 4; normalized to band intensity of corresponding GST-paxillin variant). (**F**) In vivo protein interaction and competitive binding assays in HEK293T cells transfected with various amounts (7.5 μg and 15 μg) of plasmids encoding the F-BAR domain ('F-BAR') alone or F-BAR-domain-deleted ('ΔN'-F-BAR') CIP4 and/or control vectors, as indicated. Cell lysates were immunoprecipitated by paxillin antibodies and blotted with myc or vinculin antibodies. Histograms show relative protein levels as determined by immunoblotting of vinculin co-immunoprecipitated by paxillin antibodies (±SEM, n = 3; \*p\<0.05, *t* test).](elife-31101-fig4){#fig4}

Next, we examined whether binding of paxillin to endocytic or adhesion factors is competitive. Structurally, paxillin is an adaptor protein composed of N-terminal LD motifs and C-terminal LIM domains, both of which are important for binding to focal adhesion factors ([@bib5]; [@bib6]). Among those factors, vinculin exhibits a well-characterized paxillin-binding subdomain or 'PBS' ([@bib69]; [@bib77]). By evaluating potential structural similarities between endocytic factors and the vinculin PBS, we found that the F-BAR domain of CIP4 shares the greatest degree of similarity with the PBS ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). To ascertain whether this domain binds paxillin, we used GST-fused full-length paxillin (GST-PXN^FL^) to pull down bacterially expressed, histidine-tagged full-length (His-CIP4^FL^) or F-BAR domain-deleted (His-CIP4^ΔF-BAR^) CIP4. Both proteins were HPLC-purified and biochemically confirmed by mass spectrometry. GST-PXN^FL^ associated with His-CIP4^FL^ but not His-CIP4^ΔF-BAR^ ([Figure 4B](#fig4){ref-type="fig"}), confirming that the F-BAR domain is required for paxillin binding.

Furthermore, using an in vitro GST pulldown assay and domain mapping analysis in HEK293T cell lysates, we found that deletion of the LIM3-4 domain reduced paxillin affinity for vinculin and CIP4 ([Figure 4C,D](#fig4){ref-type="fig"}). However, the paxillin interaction domains for vinculin and CIP4 do not fully overlap, as vinculin and CIP4 primarily associated with LD motifs (LD1, 2, and/or 4; \[[@bib71]\]) and the LIM domain, respectively ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). In addition, deletion of LIM domains and the last two LD domains (as seen in the paxillin^LD1-3^ construct) was required to completely attenuate binding of vinculin and CIP4 to paxillin (see [Figure 4C,D](#fig4){ref-type="fig"}). Given that CIP4 dimerizes in vitro and in vivo via its F-BAR domain (as verified by small angle X-ray scattering analysis), we asked whether increased CIP4 binding to paxillin LIM domains may spatially hinder vinculin from accessing the LD motifs. Indeed, ectopic expression of full-length CIP4 or the F-BAR domain alone in HEK293T cells decreased association of both GST-PXN^FL^ ([Figure 4E](#fig4){ref-type="fig"}) and endogenous paxillin ([Figure 4F](#fig4){ref-type="fig"}) with vinculin dose-dependently, but ectopic expression of the F-BAR-deleted CIP4 mutant (ΔN\'-F-BAR) did not ([Figure 4F](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1B--D](#fig4s1){ref-type="fig"}). In addition, competition assays using the paxillin variants GST-PXN^FL^, GST-PXN^ΔLD1^, and GST-PXN^ΔLIM3-4^ showed that the CIP4-binding LIM 3--4 region, but not the vinculin-binding LD1 motif, is required for high affinity CIP4 binding, as CIP4 could not out-compete vinculin for binding to the paxillin-∆LIM3-4 construct ([Figure 4E](#fig4){ref-type="fig"}, and [Figure 4---figure supplement 1F](#fig4s1){ref-type="fig"}). These findings indicate that endocytic factors interact with the paxillin LIM domain and are suggestive of a competitive-binding mechanism.

Paxillin is required for robust neurite formation on soft substrates {#s2-7}
--------------------------------------------------------------------

Given that endocytic activity is required for neurite initiation on a soft substrate, we wondered whether paxillin and CIP4 function in endocytosis. To assess this, we evaluated FM4-64 uptake in hippocampal neurons grown on soft substrates with or without paxillin/CIP4 knockdown by shRNA ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Reducing paxillin and CIP4 levels in this way significantly decreased the rate and level of FM4-64 uptake (endocytosis) in neurons grown on soft gels (0.1 kPa; [Figure 5A,C](#fig5){ref-type="fig"} and [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). This outcome was not seen following ectopic expression of the shRNA-resistant paxillin mutant PXN-R ([Figure 5A,C](#fig5){ref-type="fig"}). Furthermore, ectopic expression of full-length paxillin potentiated FM4-64 uptake in neurons grown on both soft and stiff gels (0.1 kPa or 20 kPa; relative to untransfected neighboring control cells); an effect not seen following ectopic expression of paxillin^ΔLIM3-4^ or paxillin^LD1-3^, which lacks the LIM-domain required for CIP4 association ([Figure 5B,D and E](#fig5){ref-type="fig"}). These findings suggest that paxillin assists endocytosis on soft substrates via its interaction with components of the endocytic machinery. Note that in neurons cultured on 20 kPa gels, but not on 0.1 kPa gels, we observed an altered CIP4 distribution along the enlarged lamella edge ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}); a pattern similar to that reported for coverslips ([@bib63]) on which the endocytic role of CIP4 may have been compromised.

![Paxillin is required for endocytosis promoted by a soft surface.\
(**A**) Paxillin knockdown suppresses the endocytic activity of neurons grown on 0.1 kPa gels. Representative time-lapse images of FM4-64 uptake in 3-DIV neurons on substrates of varying elasticity. Hippocampal neurons on 0.1 kPa gels were transduced with lentiviral particles harboring an shRNA-resistant construct ('PXN-R') and/or constructs harboring scrambled control or paxillin ('PXN shRNA C + D') shRNA at 5 hr after cell plating. Dashed circles surround the region of interest (ROI) in quantitative FM4-64 measurements. Bar: 20 μm. (**B**) Similar to **A**, except constructs encoding GFP fusions of wild-type paxillin ('PXN^WT^-GFP'; **B1 and B2**) or the corresponding LIM domain deletion mutant ('PXN^LD1-3^-GFP'; **B3**) were used for lentiviral transduction. Asterisk: non-transduced neighboring cells. Arrows: neurons expressing GFP-tagged paxillin proteins. Bar: 20 μm. (**C--E**) Quantitative measurements of cumulative FM4-64 intensity (±SEM, n \> 3 independent experiments, 7--12 cells for each set of experiments; \*p*\<*0.05; \*\*p\<0.001; \*\*\*p\<0.0001; compared to control groups; multiple *t* tests), all from experiments similar to those described in **A** and **B**. Note that ectopic expression of wild-type paxillin, but not PXN^LD1-3^, restored rapid endocytic FM4-64 uptake on 20 kPa stiff gels.](elife-31101-fig5){#fig5}

Based on its physical and functional association with CIP4 and CHC ([Figure 4](#fig4){ref-type="fig"} and [Figure 5](#fig5){ref-type="fig"}), we wondered whether paxillin might participate in vesicle invagination during clathrin-coated pit formation. To test this possibility, we quantified QD-BDNF invagination in HEK293T cells with or without paxillin knockdown. Note that HEK293T cells respond to BDNF only when transfected with a BDNF receptor (TrkB) expression construct (see [Figure 6A](#fig6){ref-type="fig"}). We did not observe detectable QD-BDNF invagination into non-TrkB-expressing HEK293T cells but, following transfection of cells with a TrkB expression construct, we observed an average invagination rate of \~32 dots per cell over the first hour after bath application of QD-BDNF. That rate significantly decreased to four dots per cell on paxillin knockdown, and comparable results were seen following CIP4 knockdown or dynasore treatment ([Figure 6A,B](#fig6){ref-type="fig"}). The decreased rates were rescued by ectopic expression of shRNA-resistant PXN-R in the paxillin knockdown experiment ([Figure 6A](#fig6){ref-type="fig"}). These findings suggest that paxillin is required for efficient vesicle invagination.

![Paxillin facilitates QD-BDNF uptake.\
(**A**) QD-BDNF internalization assay on HEK293T cells co-transfected with expression vectors encoding the BDNF receptor TrkB (Red), together with shRNA constructs (Green) and/or wild-type paxillin, as indicated. Histograms showing that co-transfection of paxillin shRNA C and shRNA D significantly reduced QD-BDNF internalization (as reflected by an \~8-fold reduction in the quantity of intracellular QD-BDNF). Data represent means ±SEM (n ≥ 3 independent experiments, 26--52 cells for each set of experiments; compared to scrambled shRNA control; \*\*\*p\<0.001; ANOVA with *Dunnett's post hoc* test). (**B**) Similar to **A**, except cells were pre-incubated with or without the dynamin inhibitor dynasore (50 μM, 30 min). Histograms show that dynamin is required for paxillin to promote QD-BDNF internalization. Data represent means ±SEM (n ≥ 3 independent experiments, 21--58 cells for each set of experiments; compared to GFP control; \*\*\*p\<0.001; ANOVA with *Dunnett's post hoc* test).](elife-31101-fig6){#fig6}

The effect of paxillin loss on neurite formation was further evaluated by measuring the rate at which paxillin knockdown cells enter a segmentable state. On soft substrates (0.1 kPa), paxillin knockdown significantly increased the percentage of neurons exhibiting the BL morphology and reduced the number of neurons bearing neurites in 16 hr cultures, with these effects being similar to those seen following treatment with the endocytosis inhibitors ([Figure 2B](#fig2){ref-type="fig"}, and [Figure 7A,B](#fig7){ref-type="fig"}). Further, paxillin knockdown significantly reduced levels of active Rac1 accumulation at the protruding edge ([Figure 7C,D](#fig7){ref-type="fig"}). These findings suggest that paxillin is a putative factor participating in a substrate modulus-dependent bistable switch in neurite formation in vitro ([Figure 7H](#fig7){ref-type="fig"}). We also asked whether manipulating paxillin binding affinity for endocytic or adhesion molecules could lead to a SL-BL phenotypic switch. Based on the domain mapping results in [Figure 4C](#fig4){ref-type="fig"}, we conclude that the paxillin-∆LD1 variant favors CIP4/clathrin association and that paxillin-∆LIM3-4 favors vinculin association. Using this approach, we found that ectopic PXN^∆LIM3-4^ expression in 0.1 kPa cultures enhanced the neuritogenesis-delaying BL phenotype, whereas PXN^∆LD1^ expression reduced the BL population in 20 kPa cultures ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). By contrast, ectopic expression of PXN^LD1-3^, which cannot bind vinculin or CIP4, had no significant effect on neurite outgrowth ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). These results support the idea that whether paxillin forms a complex with either endocytic or adhesion molecules determines the probability that newborn neurons will form proper neurites.

![Paxillin knockdown alters neurite formation and neuronal migration in vitro and in vivo.\
(**A** and **B**). Paxillin knockdown impairs lamellipodium segmentation and neurite formation in neuronal cultures on 0.1 kPa gels. (**A**) Images of 16 hr hippocampal neurons transfected with scrambled control or paxillin siRNA at 30 min after cell plating on 0.1 kPa gels, followed by phalloidin staining for F-actin (Red) and immunostaining for the neuronal marker Tuj-1 (Green) at 16 hr after cell plating. (**B**) Histograms showing that paxillin knockdown significantly decreased the percentage of neurite-bearing neurons (left y-axis) and increased the percentage of neurons exhibiting the BL phenotype (right y-axis) in 0.1 kPa cultures. Data represent mean (±SEM; n \> 3 independent experiments, \>250 cells for each group; \*p\<0.05; \*\*p\<0.01; *t* test). (**C**) Similar to **A**, except that 16 hr neuronal cultures were immunostained with antibodies against active Rac1-GTP (Gray). Fluorescence intensity of active Rac1 (boxed region) is coded by pseudocolors in the linear scale (right panel in **C**). Scale bar: 20 μm. (**D**) Quantification of active Rac1 levels at segmented lamellipodia (averaged pixel value of a 2 µm X 2 µm area) in 0.1 kPa cultures transfected with paxillin-siRNA or control scrambled siRNA. Data represent mean ±SEM (n \> 3 independent experiments, \>250 cells for each group; \*\*\*p\<0.001; ANOVA with *Dunnett's post hoc* test). (**E**) Paxillin knockdown promotes aberrant neurite formation and cortical neuron migration in vivo. Fluorescence images of E20 rat cortices transfected in utero at E17.5 with IRES constructs harboring EGFP plus scrambled-shRNA control, paxillin shRNA C + D, and/or shRNA C + D resistant PXN-R. The middle panels show 4x magnifications of boxed regions of the corresponding E20 cortex in the top panels. Bottom panels show sample tracings of 2D projections from confocal images of eight typical cortical neurons in the subventricular zone ('SVZ') of the corresponding E20 cortex. Bar, 100 μm. (**F**) Histograms showing the percentage (±SEM, n = 3 cortices each; \*p\<0.05, two-tailed *t* test) of neurons residing in the cortical plate ('CP'), intermediate zone ('IZ'), or subventricular zone ('SVZ') regions. (**G**) Calculation of the percentages (±SEM, n \> 150 cells per cortex,\>5 cortices each; \*\*\*p\<0.001, multiple *t* test) of transfected cortical neurons exhibiting unipolar/bipolar processes or no process ('none'; arrowheads in **e**) in the cortical SVZ/IZ region for cortices described in **e**. Datasets (connected by dashed lines) showing significant differences are marked. (**H**) Schematic illustrating the proposed substrate elasticity-controlled, paxillin-dependent bistable mechanism, comprising a genetic response and mutual inhibition of endocytosis by adhesion and vice versa. Growth on a soft substrate shifts neurons to a Rac1-activated neuritogenic state.](elife-31101-fig7){#fig7}

Paxillin is required for neurite development in vivo {#s2-8}
----------------------------------------------------

We next evaluated the effect of paxillin activity on neurite development in vivo by monitoring the protein expression of endocytic factors in embryonic rat brain. We observed high levels of endocytosis-related factors and low levels of adhesion-related molecules in embryonic rat brains compared to hepatic and cardiac control tissues ([Figure 7---figure supplement 2](#fig7s2){ref-type="fig"}). In addition, paxillin abundance increased between E13 and E18 and declined postnatally (between P1 and P14) in the developing cortex ([Figure 7---figure supplement 3](#fig7s3){ref-type="fig"}). This time-course is compatible with and parallels that of neurite formation in the developing rat brain.

Then, to assess the function of paxillin in neurite development in vivo, we conducted in utero electroporation of paxillin shRNA (PXN-shRNAs) in a subpopulation of neural progenitor cells at embryonic day 17 (E17). Because aberrant neurite formation in vivo usually delays neuronal migration into the cortical plate (CP) ([@bib38]), we analyzed E20 rat brain slices in which most cells (\~75%) in control embryos had migrated out of the subventricular zone (SVZ) with a radial infiltration into the intermediate zone (IZ) toward the CP ([Figure 7E,F](#fig7){ref-type="fig"}). Neurons expressing paxillin-shRNA showed apparent migration defects relative to controls, with \~42% of cells accumulating in the SVZ, wherein \~25% of paxillin-knockdown neurons did not exhibit neurite processes ([Figure 7E,G](#fig7){ref-type="fig"}). These phenotypes were rescued by co-expression of shRNA-resistant PXN-R ([Figure 7E--G](#fig7){ref-type="fig"}).

Discussion {#s3}
==========

Neurite formation is the first morphogenetic step in establishing axonal projections and dendritic territory. Under physiological environments in vivo, both genetic programs and cell mechanics contribute to timely emergence of neuronal morphology and activity. Nevertheless, it remains challenging to define spatio-temporal patterns of neurite initiation and most studies to date have tackled this question using thin-glass or plastic cell culture substrates in which cell-matrix adhesion is a prominent response. In the present study, we used culture on soft substrates to demonstrate a paxillin-linked bistable switch that governs the ability of newborn neurons to shift their lamellipodium morphology to one of two stable states and to assume a neuritogenic state within a few hours. Our system recapitulates temporal and morphologic features observed in vivo. By contrast, when cells are grown on rigid substrates or when endocytosis is inhibited, neurons adopt the behavior of most migratory cells and paxillin becomes associated with cell-matrix or adhesion factors, exhibiting broad lamellipodia that delay neurite formation. Such biphasic neurite initiation emerges from an amplification loop enabling mutual inhibition of endocytosis by the adhesion machinery, and vice versa ([Figure 7H](#fig7){ref-type="fig"}). Through this mechanism, newborn neurons can respond to the soft environments that dictate a phenotypic switch to allow neurite initiation. Our findings also complement previous views of neurite formation defined by conventional Banker's culture on coverslips.

To form protrusions from a cell body, cells must coordinate several distinct intracellular mechanisms, including actin retrograde flow ([@bib23]; [@bib27]), actomyosin-generated contractility ([@bib1]; [@bib59]), membrane fusion and/or membrane tension ([@bib30]; [@bib81]), and exo- and endocytic pathways ([@bib58]). It is not surprising that paxillin is involved in these processes, given its role as an integrator of integrin and growth factor signaling ([@bib7]). What is striking is our finding that paxillin plays a dual role in adhesion and endocytosis, with predominance of one of these roles determining the fate of a newborn neuron. Historically, paxillin has been known as a major player in cell-matrix adhesions, where it associates with tyrosine kinases (such as FAK and Src) and the actin-binding proteins vinculin and actopaxin ([@bib5]; [@bib7]; [@bib52]; [@bib66]; [@bib73]). Our findings suggest that on soft gels in particular, newborn neurons recruit paxillin to the endocytic machinery (via binding with clathrin and CIP4) with a higher, but not exclusive, preference over cell-matrix adhesions. Our microarray analysis indicates that selectively elevated levels of endocytic factors may underlie their preferential recruitments with paxillin observed in soft-gel cultures. This heretofore unknown behavior of paxillin then elevates endocytic activity, Rac1 signaling, and expression of the genes encoding endocytic proteins that are required for timely neurite emergence. As a result, a soft environment with elasticity lower than 1 kPa is sufficient to induce timely neurite initiation. Conversely, our observations suggest that culturing cells on rigid substrates, disruption of Rac1 activation, and blockage of endocytosis all delay spontaneous neurite initiation.

Proper functioning of neural networks depends on physical connections between neurons, such as synapses, which in turn requires the capacity to control morphological changes such as protrusion in the course of neuritogenesis. For most cells, microenvironmental stiffness has been shown to promote cell spread and protrusion ([@bib17]; [@bib80]). However, those same environments may lead to formation of unnecessary connections in young neurons or even promote deleterious 'noise' that can interfere with neuronal function. The ability of neonatal neurons to delay neuritogenesis on a rigid environment could endow cells with the ability to establish robust and functional networks only in permissive environments (i.e. soft microenvironments). While paxillin functions in endocytic reactions as opposed to adhesion upon neurite initiation on soft substrates, endocytic accessory components could have an unconventional role when endocytic signaling becomes compromised under high cell-matrix adhesion regimes. For example, ectopically expressed CIP4 has been shown to accumulate at broad lamellipodia and to inhibit neurite formation on stiff substrata (coverslips) ([@bib63]), where CIP4 may function in actin polymerization rather than neuritogentic endosomal reactions.

Paxillin-associated endocytosis may also occur in epithelial cells, since both epithelial cells and neurons are derived from ectoderm. In fact, in vitro experiments demonstrate that proper development of epithelial organs requires soft microenvironments, while stiff stroma is often observed in advanced cancers ([@bib32]; [@bib57]; [@bib75]). By comparison, muscle cells, fibroblasts or osteoclasts, which are derived from other germ layers, may exhibit higher tension or rigidity. Based on studies reporting the natural stiffness of mouse embryonic cerebral cortex at E16.5 to E18.5 ([@bib41]), we surmise that a neuronal switch favoring paxillin/endocytic factor binding is required and activated immediately after embryonic neuronal differentiation to ensure timely neurite initiation. This switch may also promote departure of cells from neurogenic regions, such as the ventricular and subventricular zones, whose stiffness is relatively high compared to the cortical plate at E18.5. However, at a later developmental time-point (since brain stiffness increases with age) and at synaptic contact sites, the paxillin adhesion switch may predominate, allowing contacts with postsynaptic cells or decreasing the capacity for neurite outgrowth. For example, synapses at neuro-muscular junctions where repetitive muscle contraction can endow much greater localized stiffness than that seen in brain cortex may favor paxillin/adhesion machinery association. Furthermore, as shown here, the paxillin adhesion switch relies on formation of adhesion complexes and consequently depends on integrin signaling. In developing and adult brain, integrins play important roles in controlling neuronal process outgrowth and regulating synaptic plasticity and memory formation (reviewed in \[[@bib56]\]). However, the paxillin-mediated switch to control timing of neurite initiation may not underlie morphogenetic events occurring at later stages, as neuronal paxillin expression decreases as neurons mature. Therefore, it will be important to revisit the relationship among genetic profiles, cellular reactions, and tissue mechanical properties over different cell types and developmental stages.

Looking forward, our observations and our model for a molecular switch that is integrated with changes in gene expression and the dual role of paxillin represent a robust mechanism that could underlie synchronous behaviors, such as morphological transformation or cohort migration, that occur when a group of developing cells is exposed to diverse signals in vivo. Besides substrate stiffness, physiological constraints imposed by other factors, such as cell-cell contact guidance or actin-microtubule coupling efficiency, could play important roles in neurite formation. In addition to a morphogenetic role, paxillin-associated endocytosis may also potentiate retrograde relay of growth and survival signals deployed from the neuritic terminal ([@bib12]) and thereby provide another mechanism to positively regulate neuronal development.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\   Designation                         Source or reference               Identifiers                                                                  Additional information
  or resource                                                                                                                                                                  
  ------------------------- ----------------------------------- --------------------------------- ---------------------------------------------------------------------------- --------------------------
  cell line                 HEK293T                             ATCC                              ATCC Cat\# CRL-3216,\                                                        
                                                                                                  RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)                   

  antibody                  anti-FLAG M2                        Sigma-Aldrich                     Sigma-Aldrich Cat\# F1804,\                                                  dilution: 1:1000
                                                                                                  RRID:[AB_262044](https://scicrunch.org/resolver/AB_262044)                   

                            c-Myc Tag Monoclonal\               Thermo Fisher Scientific          Thermo Fisher Scientific\                                                    dilution: 1:1000
                            Antibody (9E10)                                                       Cat\# MA1-980,\                                                              
                                                                                                  RRID:[AB_558470](https://scicrunch.org/resolver/AB_558470)                   

                            Anti-beta III tublin\               Millpore                          Millipore Cat\# AB9354,\                                                     dilution: 1:1000 in IF
                            Antibody                                                              RRID:[AB_570918](https://scicrunch.org/resolver/AB_570918)                   

                            MAP2                                Millpore; PMID:26244549           Millipore Cat\# AB5622,\                                                     dilution: 1:1000 in IF
                                                                                                  RRID:[AB_11213363](https://scicrunch.org/resolver/AB_11213363)               

                            actin                               Millpore                          Millipore Cat\# MAB1501,\                                                    dilution: 1:2000
                                                                                                  RRID:[AB_2223041](https://scicrunch.org/resolver/AB_2223041)                 

                            Tau-1                               Millpore                          Millipore Cat\# MAB3420,\                                                    dilution: 1:1000 in IF
                                                                                                  RRID:[AB_94855](https://scicrunch.org/resolver/AB_94855)                     

                            Anti-Paxillin (N-Term),\            Millpore                          Millipore Cat\# 04--581,\                                                    dilution: 1:1000 in WB;\
                            Rabbit Monoclonal,\                                                   RRID:[AB_838293](https://scicrunch.org/resolver/AB_838293)                   1:200 in IF
                            clone Y113 antibody                                                                                                                                

                            p-PaxillinY118                      ECM Biosciences                   ECM Biosciences Cat\# PP4501                                                 dilution: 1:1000

                            Mouse Anti-Paxillin\                BD Biosciences; PMID:28362576     BD Biosciences Cat\# 612405,\                                                dilution: 1:1000
                            Monoclonal Antibody,\                                                 RRID:[AB_647289](https://scicrunch.org/resolver/AB_647289)                   
                            Unconjugated, Clone 349                                                                                                                            

                            Anti-Vinculin, clone\               millpore; PMID:28697342           Millipore Cat\# 05--386,\                                                    dilution: 1:1000 in WB;\
                            V284 antibody                                                         RRID:[AB_309711](https://scicrunch.org/resolver/AB_309711)                   1:200 in IF

                            Anti-Integrin Beta1,\               Millore; PMID:28602620            Millipore Cat\# MAB2079Z,\                                                   dilution: 1:1000
                            activated, Clone HUTS-4,\                                             RRID:[AB_2233964](https://scicrunch.org/resolver/AB_2233964)                 
                            Azide Free antibody                                                                                                                                

                            TRIP/CIP4                           Bethyl Laboratories; A301-186A                                                                                 dilution: 1:1000 in WB;\
                                                                                                                                                                               1:200 in IF

                            Clathrin heavy chain antibody       Abcam; PMID:28231467,\            Abcam Cat\# ab21679,\                                                        dilution: 1:1000 in WB;\
                                                                PMID:28575669                     RRID:[AB_2083165](https://scicrunch.org/resolver/AB_2083165)                 1:200 in IF

                            Talin 1 and 2 antibody \[8D4\]      Abcam                             Abcam Cat\# ab11188,\                                                        dilution: 1:1000 in WB
                                                                                                  RRID:[AB_297828](https://scicrunch.org/resolver/AB_297828)                   

                            Rabbit Anti-Rab5 Polyclonal\        Abcam; PMID:28408870,\            Abcam Cat\# ab18211,\                                                        dilution: 1:1000 in WB
                            Antibody, Unconjugated              PMID:28669519                     RRID:[AB_470264](https://scicrunch.org/resolver/AB_470264)                   

                            Integrin beta 1\                    Abcam; PMID:25330147,\            Abcam Cat\# ab52971,\                                                        dilution: 1:1000 in WB;\
                            antibody \[EP1041Y\] -\             PMID:28552668,\                   RRID:[AB_870695](https://scicrunch.org/resolver/AB_870695)                   1:200 in IF
                            Carboxyterminal end                 PMID:28609658                                                                                                  

                            Phospho-FAK (Tyr397)\               Thermo Fisher Scientific;\        Thermo Fisher Scientific\                                                    dilution: 1:1000 in WB;\
                            Antibody (31H5L17), ABfinity(TM)\   PMID:22049075, PMID:25280968,\    Cat\# 700255, RRID:[AB_2532307](https://scicrunch.org/resolver/AB_2532307)   1:200 in IF
                            Rabbit Monoclonal                   PMID:26056143, PMID:26381152,\                                                                                 
                                                                PMID:26393679, PMID:26984758                                                                                   

                            Rabbit Anti-FAK \[pY397\]\          Thermo Fisher Scientific;\        Thermo Fisher Scientific\                                                    dilution: 1:1000 in WB;\
                            Polyclonal Antibodies,\             PMID:27474796,\                   Cat\# 44--624G,\                                                             1:200 in IF
                            Unconjugated antibody               PMID:28069919, PMID:28520937      RRID:[AB_2533701](https://scicrunch.org/resolver/AB_2533701)                 

                            Akt1/2/3 (H-136) antibody           Santa Cruz Biotechnology;\        Santa Cruz Biotechnology\                                                    dilution: 1:200 in WB
                                                                PMID:27316329,\                   Cat\# sc-8312, RRID:[AB_671714](https://scicrunch.org/resolver/AB_671714)    
                                                                PMID:27410235, PMID:28911175                                                                                   

                            Rac 1 (C-11) antibody               Santa Cruz Biotechnology          Santa Cruz Biotechnology\                                                    dilution: 1:200 in WB
                                                                                                  Cat\# sc-95,\                                                                
                                                                                                  RRID:[AB_2176125](https://scicrunch.org/resolver/AB_2176125)                 

                            Cdc42 (P1) antibody                 PMID:28181299, PMID:28457749      Santa Cruz Biotechnology\                                                    dilution: 1:200 in WB
                                                                                                  Cat\# sc-87,\                                                                
                                                                                                  RRID:[AB_631213](https://scicrunch.org/resolver/AB_631213)                   

                            Rho A (26C4) antibody               Santa Cruz Biotechnology;\        Santa Cruz Biotechnology\                                                    dilution: 1:200 in WB
                                                                PMID:28287395, PMID:28323616      Cat\# sc-418,\                                                               
                                                                                                  RRID:[AB_628218](https://scicrunch.org/resolver/AB_628218)                   

                            Anti-Active Rac1-GTP Mouse\         NewEast Biosciences               NewEast Biosciences\                                                         dilution: 1:200 in\
                            Monoclonal Antibody                                                   Cat\# 26903,\                                                                WB and IF
                                                                                                  RRID:[AB_1961793](https://scicrunch.org/resolver/AB_1961793)                 

                            Anti-RhoA antibody (mouse\          Cytoskeleton Inc; PMID:27822498   Cytoskeleton Cat\# ARH03,\                                                   dilution: 1:200 in\
                            MAb)+control                                                          RRID:[AB_10708069](https://scicrunch.org/resolver/AB_10708069)               WB and IF

                            Anti-Rac1 specific\                 Cytoskeleton Inc                  Cytoskeleton Cat\# ARC03-A,\                                                 dilution: 1:200 in\
                            mouse MAb antibody                                                    RRID:[AB_10709099](https://scicrunch.org/resolver/AB_10709099)               WB and IF

                            Anti-Cdc42 Mouse\                   Cytoskeleton Inc                  Cytoskeleton Cat\# ACD03-A,\                                                 dilution: 1:200 in\
                            Monoclonal Antibody                                                   RRID:[AB_10716593](https://scicrunch.org/resolver/AB_10716593)               WB and IF

  peptide, recombinant\     PAK-GST, GST-Photekin-RBD           Cytoskeleton Inc                  Cytoskeleton Inc Cat.\                                                       
  protein                                                                                         \#BK035; Cat. \# BK036                                                       
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Plasmids {#s4-1}
--------

Plasmids used are as follows: fluorescence resonance energy transfer (FRET) reporters for Rac1 activity assays, Rac1-2G (Plasmid \#66111; \[[@bib28]\], GFP-Dynamin 2 K44A (Plasmid \#22301;([@bib54]) and paxillin-pEGFP plasmid (Plasmid \# 15233; ([@bib43]) were obtained from Addgene. Lentiviral transfer plasmid pLenti-C-Myc-DDK-CIP4 (also known as TRIP10) was generated by subcloning the C-Myc-DDK-CIP4 fragment from pCMV-C-Myc-DDK-TRIP10 (OriGene Technologies, Rockville, MD) into pLenti vector using AsiSI and PmeI restriction sites. GST- or His-tagged fusion protein expression constructs encoding full-length or truncated versions of paxillin or CIP4 were cloned into pDONR/Zeo vectors (Invitrogen, Carlsbad, CA) by PCR-based methods and transferred to T7 promoter-driven pDEST15 or pEXP2-6xHis-DEST Gateway destination vectors (Invitrogen, Carlsbad, CA) by recombination‐based Gateway technology according to the manufacturer\'s protocols (Invitrogen, Carlsbad, CA). Paxillin-mCherry plasmid was generated by replacing the EGFP fragment from paxillin-pEGFP with the mCherry sequence. Lentiviral-based short hairpin RNA (shRNA) constructs were purchased from OriGene Technologies (Rockville, MD). For paxillin shRNA constructs, 29-oligonucleotide duplexes targeting rat paxillin cDNA sequences (PXN-shRNA A targeting position 1505, PXN-shRNA B targeting position 1571, PXN-shRNA C targeting position 346, and PXN-shRNA D targeting position 952 of the corresponding paxillin sequence) and a control non-effective scrambled shRNA cassette (5'- CACAAGCTGGAGTACAACTACAACAGCCA-3') were cloned into pGFP-C-shLenti vector (OriGene Technologies, Rockville, MD). For CIP4 shRNA constructs, TRIP10-shRNA A targeting position 172, TRIP10-shRNA B targeting position 351, TRIP10-shRNA C targeting position 811, and TRIP10-shRNA D targeting position 983 of the corresponding CIP4 coding sequence were also cloned into pGFP-C-shLenti vector (OriGene Technologies, Rockville, MD). The encoding regions of shRNAs contained a 29-nucleotide sense strand, a TCAAGAG loop structure, and the reverse complementary sequence, followed by a TTTTTT termination sequence. The chicken ortholog of a mammalian paxillin expression plasmid, paxillin-pEGFP, was used as the shRNA-resistant construct (PXN-shRNA-R), the sequence of which is resistant to PXN-shRNA targeting. pLenti-C-mGFP-PXN (rat paxillin) was purchased from OriGene Technologies (Rockville, MD). The plasmid encoding mCherry-TrkB used in QD-BDNF internalization assays was kindly provided by Dr. Mu-Ming Poo, UC Berkeley, USA.

Reagents {#s4-2}
--------

Sources of antibodies, proteins, and chemicals are as follows. Purified PAK-GST and GST-Rhotekin-RBD for active Rac1 and RhoA pulldown assays were from Cytoskeleton Inc. (Denver, CO). Primary antibodies: monoclonal anti-FLAG M2 was from Sigma-Aldrich (Saint Louis, MO). Polyclonal antibodies to neuronal class III β-tubulin (Tuj-1, AB9354) and MAP2 (AB5622), as well as monoclonal antibodies to actin (clone C4, MAB1501), Tau-1 (clone PC1C6, MAB3420), paxillin (N-term, 04--581), vinculin (clone V284, 05--386) and activated integrin β1 (clone HUTS-4, MAB 2079Z) were from EMD Millipore Corp. (Billerica, MA). Polyclonal antibodies to TRIP/CIP4 (A301-186A). was from Bethyl Laboratories, Inc. (Montgomery, TX). Clathrin heavy chain (ab21679), Rab5 (ab18211), and monoclonal antibodies to integrin β1 (ab52971) and talin 1/2 (ab11188) were from Abcam Inc. (Cambridge, MA). Polyclonal antibody to p-FAK^Y397^(44--624G) and monoclonal antibody to p-FAK^Y397^ (700255) were from Thermo Fisher Scientific. Polyclonal antibody to p-Paxillin^Y118^ (PP4501) was from ECM Biosciences (Versailles, KY). Monoclonal antibody to paxillin (612405) was from BD Biosciences (Franklin Lakes, NJ). Polyclonal antibodies to Akt1/2/3 (H-136), Rac1 (C-11, sc-95), Cdc42 (P1, sc-87), as well as monoclonal antibody to RhoA (26C4, sc-418), were from Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody to c-Myc (9E10, MA1-980) was from Thermo Scientific (Waltham, MA). Monoclonal antibody to active Rac1-GTP (26903) was from NewEast Biosciences (King of Prussia, PA). Monoclonal antibodies to RhoA (ARH03), Rac1 (ARC03) and Cdc42 (ACD03) were from Cytoskeleton Inc. (Denver, CO).

Pharmacological reagents: recombinant human BDNF was from PeproTech (Rocky Hill, NJ). PP2 (Src and RIP2 kinase inhibitor, ab120308), Dynole2--24 (potent dynamin I and II inhibitor; ab141290), and Dyngo 4a (ab120689; highly potent dynamin inhibitor) were purchased from Abcam Inc. (Cambridge, MA). Actinomycin D (A9415), dynasore (D7693) and dansylcadaverine (also described as monodansyl cadaverine (MDC), 30432) were purchased from Sigma Aldrich (Saint Louis, MO). PD150606 (1269) and NSC23766 (2161) were purchased from Tocris Bioscience (Ellisville, MO). LY 294002 (440202) and Y-27632 (SCM075) were bought from EMD Millipore Corp. (Billerica, MA).

Fluorescent reagents: Alexa Fluor 488, Alexa Fluor 546, Alexa Fluor 647, fluorescent dye FM1-43FX (F35355) and FM4-64FX (F34653) were from Invitrogen (Carlsbad, CA). DAPI (D9542), Acrylamide (A4058) and N\'-N\'-methylenebisacrylamide solution (M1533) were purchased from Sigma-Aldrich (Saint Louis, MO). Phalloidin-iflour 488 conjugate, phalloidin-iflour 555 conjugate and phalloidin-iflour 647 conjugate were from AAT Bioquest Inc. (Sunnyvale, CA).

Cell culture, protein lysate preparations, and immunostaining {#s4-3}
-------------------------------------------------------------

Hippocampal neurons were prepared from E17.5 rat embryos as previously described ([@bib18]), and were cultured in neurobasal medium supplemented with Gem21 NeuroPlex (GEMINI bio-products, West Sacramento, CA). A similar procedure was applied to preparation of cortical neuronal cultures. Human Embryonic Kidney 293T (HEK293T; ATCC Cat\# CRL-3216) cells used for biochemical assays were tested for Mycoplasma and characterized by STR profiling as indicated in the ATCC online catalog. HEK293T cells were cultured in Dulbecco\'s Modified Eagle\'s Medium supplemented with 10% fetal bovine serum (Biological Industries, Beit Haemek, Israel). Transfection of these cultures was performed using a lentivirus-based expression system or Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer\'s instructions. Unless otherwise stated, hippocampal neurons were used as a standard model for in vitro immunocytochemistry to analyze neuronal morphology. Cortical neuronal cultures were used to obtain a sufficient number of cells for biochemical assays not requiring transfection of exogenous proteins.

For cortical neurons grown on gel or glass substrates, protein lysate was harvested in RIPA buffer (Sigma Aldrich, St. Louis, MO) containing complete protease inhibitor cocktail (Roche, BASEL, Switzerland) and phosphate inhibitor PhosSTOP (Roche, BASEL, Switzerland). For tissue lysate preparations, brain and heart were dissected out from E17.5 rat embryos and rinsed briefly with PBS, followed by tissue homogenization using a pestle in ice-cold lysis buffer (20 mM Tris-HCl, 5 mM MgCl~2~ and 1 mM DTT), followed by four rounds of sonication (20 s on followed by 10 s off). For other biochemical experiments, cell lysates were prepared by the freeze-thaw method.

For immunostaining, cultured hippocampal neurons were fixed with 4% paraformaldehyde for 12 min and then permeabilized in 0.3% Triton X-100 for 12 min and blocked with 3% BSA for 1 hr. The fixed cells were processed further for immunostaining according to standard procedures and imaged with a confocal microscope (Zeiss LSM700) equipped with a 63 × oil immersion objective (NA1.4; Zeiss) and a 40 × water immersion objective (NA1.1; Zeiss). For quantitative measurements of colocalization, images were acquired using a Zeiss LSM880 confocal microscope with an Airyscan module (32-channel GaAsP detector array) equipped with a Plan Apo 63 × oil immersion objective (NA1.4). The axial step size was set to 125 nm. Surface rendering of the three-dimensional images was performed using ZEN (Zeiss) and Imaris (Bitplane) software without Z-correction. Images were analyzed and processed for presentation in the figures, using brightness and contrast adjustments with NIH ImageJ software and following the guidelines of Rossner and Yamada ([@bib62]).

Polyacrylamide gel preparation {#s4-4}
------------------------------

Fabrication of polyacrylamide gels with tunable mechanical stiffness was slightly modified from a previous protocol ([@bib70]). Briefly, uniform polyacrylamide gels were fabricated in a three-layer assembly of 200 μm thickness. The bottom layer was a hydrophilic amino-silanized coverslip prepared according to the following protocol. A thin film of sodium hydroxide was allowed to form on the coverslips at approximately 90°C. The entire surface of each coverslip was then immersed with a sufficient volume of (3-aminopropyl) triethoxysilane (Sigma-Aldrich, Saint Louis, MO) for 5 min. The (3-aminopropyl) triethoxysilane was then completely rinsed off to prevent precipitation before 0.5% (v/v) glutaraldehyde (Sigma-Aldrich, Saint Louis, MO) in PBS was added onto the silanized coverslips for 30 min. Fluids were removed by suction before the amino-silanized coverslips were air-dried and sterilized with 70% ethanol for 16 hr prior to gel preparation. The top layer comprised a laminin-coated coverslip prepared by sterilizing an acid-washed coverslip with 70% ethanol and then coating it with 5 μg/ml of poly-L-Lysine (Sigma Aldrich, Saint Louis, MO) and 0.08 μg/ml of laminin (Corning, NY) by absorption for an hour at 37°C.

For the middle gel layers of differing stiffness, a prepolymer mixture was prepared as shown in the table below. Polymerization of the prepolymer mixture was carried out by adding 10 μl of 10% ammonium persulfate, 2 μl of TEMED (Bio-Rad Laboratories, Hercules, CA) and sufficient deionized water to yield a final volume of 1000 μl. The resulting prepolymer-catalyst mixture was dropped onto hydrophobic amino-silanized coverslips. The three-layer assembly was formed by transferring the pre-coated poly-L-Lysine and laminin coverslips to the surfaces of the polyacrylamide gels during polymerization. After 30 min, the top layer was gently peeled off and washed three times with HEPES solution to remove unreacted monomer and excess coatings.

4% acrylamide (μl)2%N\'-N\'-methylenebisacrylamide (μl)Deionized water (μl)0.1 kPa75259001 kPa1005085020 kPa200240560

Substrate elasticity measurements {#s4-5}
---------------------------------

Substrate elasticity of uniform gels was measured by using a JPK NanoWizard II AFM system installed above the stage of an inverted light microscope (Zeiss Axio Observer) in a custom-built anti-noise, anti-vibration system. A 5 µm (in diameter) polystyrene bead-modified tip-less cantilever (ARROW-TL1-50, NanoWorld, US) was utilized. The spring constants, calibrated by a thermal noise-based method, were at a range of 0.02 to 0.08 N/m for all cantilevers. All indentation depth curves were calculated using the manufacturer's software (Hertz model, JPK instruments, Berlin, Germany). The average value of Young's modulus of tensile elasticity was acquired from 25 measurements for each independent experiment.

Phalloidin intensity profiling {#s4-6}
------------------------------

Images of 5 hr neuronal cultures stained with phalloidin were analyzed in a circular coordinate system using an oval-profile ImageJ plugin (courtesy of Bill O'Connell, <http://rsbweb.nih.gov/ij/plugins/oval-profile.html>). The pixel intensities along each radian in a circle (radius = 8 µm) covering the cell periphery were normalized against the background value and plotted as an intensity-distribution profile. The lamellipodium occupancy (LO) refers to the proportion of the individual phalloidin arc length (angular span) to the entire cell periphery ($\left. 2\pi r \right)$, calculated by the formula $\frac{phalloidinarclength}{2\pi r}$. The major LO represents the maximum LO value of each cell.

Single molecule FISH {#s4-7}
--------------------

Neurons grown on gel or glass substrates were fixed in 4% paraformaldehyde at room temperature for 10 min, and then permeabilized in 0.3% Triton X-100 for 12 min and rinsed in 70% ethanol for subsequent RNA FISH. For hybridization, samples were briefly washed once with wash buffer (10% deionized formamide, 2 × SSC) for 5 min, and then hybridized with RNA FISH probes in hybridization buffer (10% formamide, 10% dextran sulfate, 2 × SSC) overnight at 37°C. Following hybridization, samples were washed twice with wash buffer (30 min per wash), and washed once with 1 × PBS. Samples were then imaged with a Delta Vision microscopy system equipped with a PlanApoN 60X oil-immersion objective (1.42 NA; Olympus). Images were collected and analyzed with NIH Image software. Alexa Fluor 488 phalloidin was used to identify the lamellipodium phenotypes of the stained cells. smRISH probe sets targeting the rat transcripts of *CLTC*, *MYO6*, *DAB2, VCL, CDH11, ROBO2, DKK1, and CYR61* were ordered from Stellaris with Quasar 570 dye (Bioserach Technologies, Petaluma, USA).

FRET imaging and analysis {#s4-8}
-------------------------

Cultured hippocampal neurons were imaged with a Rolera EM-C^2^ EMCCD camera (QImaging) and Yokogawa CSU-X1 spinning-disk confocal microscopy (Zeiss) and a 40 × water immersion objective (NA1.1; Zeiss). Excitation spectra were excited by a solid-state 445 nm diode laser, through a 457 nm dichroic filter. Emission spectra were sequentially acquired using 485 ± 20 nm and 535 ± 30 nm band-pass emission filters for mTFP1 and Venus fluorescence, respectively. Images were collected and analyzed with NIH ImageJ software. All filters and dichroics were from Chroma Technology. Live images were acquired for 150 milliseconds at 3 s intervals. The intensity of mTFP1 and Venus fluorescence was measured at a level below saturation for all neurites. Measurements were not performed on the soma due to fluorescence saturation being at the excitation level suitable for neurite measurements. For the ratiometric FRET analysis, the mTFP1 and Venus signals were background-subtracted (with background intensity taken from a nearby cell-free region), normalized against the control value (averaged over 3 min), and the FRET value was calculated as a ratio (mTFP1/Venus). The intensity of the FRET signal was calculated with NIH ImageJ software and is represented by pseudocolors.

Expression of GST- and His-tagged proteins, and in vitro binding assays {#s4-9}
-----------------------------------------------------------------------

For protein expression and purification, GST fusion proteins were produced as previously described. Briefly, GST- or His-tagged proteins were expressed in *E. coli* BL21(DE3) induced by 0.4 mM IPTG overnight at 30°C in LB medium. Bacteria were lysed by sonication in short pulses of 15 s in lysis buffer \[(50 mM Tris-HCl, pH = 7.4, 50 mM NaCl, 5 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 1% Triton X-100 containing 1% Triton X-100, 1 mM EDTA, 1 mM dithiothreitol and protease inhibitors (Complete EDTA-free; Roche)\]. Cell debris was removed by centrifugation at 9000 *g* for 10 min at 4°C. The resulting supernatant was applied onto a Glutathione Sepharose 4B or HisTrap column (GE Healthcare). After washing, GST- and His-tagged proteins were eluted in buffer containing 10 mM reduced glutathione and 300 mM imidazole, respectively. We added 1 M imidazole to samples shortly after elution to prevent precipitation of His-tagged protein. Protein concentrations were measured using the Bio-Rad DC Protein Assay. Protein purity was further assessed by fast protein liquid chromatography, followed by SDS- PAGE and Coomassie blue staining.

For GST pull-down assays, cell lysate/His-tagged protein and GST fusion proteins were incubated together with glutathione-agarose beads. Complexes recovered from the beads were resolved by SDS-PAGE and analyzed by western blotting.

FM4-64 dye imaging {#s4-10}
------------------

Hippocampal neurons grown on various substrates were starved in neurobasal medium for 30 min and transferred to extracellular solution (145 mM NaCl, 10 mM HEPES, 8 mM glucose, 3 mM CaCl~2~, 2 mM MgCl~2~ and 3 mM KCl) before loading with the fluorescent dye FM 4-64FX (Invitrogen, Carlsbad, CA). Time-lapse images of neurons loaded with 20 μM FM4-64 were acquired as 10 μm z-series stacks (spaced at 0.5 μm) at 2 min intervals for 40 min using Yokogawa CSU-X1 spinning-disk confocal microscopy (Zeiss). Image analysis of FM dye intensity of the region of interest in cell bodies was performed by NIH ImageJ software. All pictures were taken at equal exposure for control and experimental groups.

Measurements of QD-BDNF internalization {#s4-11}
---------------------------------------

Quantum dot-labeled BDNF (QD-BDNF) was prepared as previously described ([@bib78]). Briefly, streptavidin-conjugated QD655 (Invitrogen, Carlsbad, CA) mixed with human BDNF-biotin (Alomone Labs, Jerusalem, Israel) at a molar ratio of 1:2 was incubated overnight at 4°C. Unbound BDNF was separated from QD-BDNF with Sephacryl S-300 HR beads (Sigma-Aldrich, Saint Louis, MO), and the elution fractions (in 20 mM HEPES buffer, pH 7.2) with the highest fluorescence were regarded as the purified QD-BDNF. HEK293T cells transfected with TrkB expression constructs or hippocampal neurons were exposed to 0.1 nM QD-BDNF in 2% BSA containing extracellular solution for 30 min, followed by a period of washout before image acquisition. The fluorescence images of internalized QD-BDNF were acquired by spinning-disk confocal microscopy (Zeiss, multiple emission set: E460 SPUVv2, EX; 475DCXRU dichroic mirror, BS; D655/40 m, EM) in the presence of the quencher QSY-21 (2 μM) to prevent signals of extracellular QD-BDNF. We quantified amounts of BDNF-Qdots taken up by cells and correlated them with TrkB expression in transfected cells. BDNF-Qdot uptake by HEK293T cells requires TrkB expression, but TrkB levels do not show a linear correlation with numbers of intracellular BDNF-Qdots. Based on TrkB levels seen in our experiments, the amount of receptor is already saturating and sufficient to accurately assess BDNF-Qdot uptake by HEK293T cells. We omitted analysis of cells whose TrkB intensity is relatively low (cut-off = 5% of highest TrkB intensity in each group). This adjustment does not alter overall observation that loss of paxillin expression significantly reduces BDNF-Qdot uptake.

cDNA microarray and data validations {#s4-12}
------------------------------------

Total RNA of cortical neurons growing on gels of differing stiffness and glass was extracted at different time-points using a QuickGene RNA cultured cell kit from Kurabo Industries Ltd. (Osaka, Tokyo). RNA concentrations were quantified using a NanoDrop Spectrophotometer ND-1000 (NanoDrop Technologies, Wilmington, ED). RNA quality was assessed using a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) based on the following criteria: RNA integrity (number) \>8.0, rRNA ratio (28S/18S) \>1.8, and the proportion of 28S and 18S (amount) \>40%. cDNA probe labeling and hybridization on rat gene expression microarray slides (Agilent Technologies, Santa Clara, CA) was conducted according to the manufacturers' protocols and carried out in the Institute of Molecular Biology Genomics Core Facility. Microarray data (19956 entrez genes) were analyzed using GeneSpring GX software (version 12.1, Agilent). In brief, gene expression levels were subjected to quantile normalization and averaged from three independent experiments. Gene modules of the differential expressions were identified using a volcano plot (filtering criteria: \>1.5 fold change, p\<0.05, *t* test), followed by Gene Ontology analysis (cut off: p\<0.02; [Appendix 1---table 1](#app1table1){ref-type="table"}). Validation of results was achieved by overlaying the microarray-identified genes with a global molecular network (the IPA knowledge base), which revealed that the 114 genes were eligible to generate networks with a p-value\<0.02. We prioritized the 114 genes based on their significance (*p*-value), and 'endocytosis-related reaction' came out as the top-ranked GO term for molecular functions among genes in the list. Three out of 37 genes that were selectively upregulated in 5 hr 0.1 kPa cultures are directly linked to endocytic processes. Based on significant shared GO terms, the correlations between the stiffness of substrates and the expression levels of genes associated with endocytosis, adhesion, neuronal development and cytoskeleton (see [Appendix 1---table 2](#app1table2){ref-type="table"}) were further verified by using QuantiGene Plex 2.0 assays according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). The two housekeeping genes, GAPDH and HPRT, were used for data normalization. GEO accession number of the microarray data set is GSE102350.

In utero electroporation {#s4-13}
------------------------

In utero electroporation followed previously described procedures ([@bib65]), with minor modifications. Timed-pregnant Sprague-Dawley rats were anesthetized at E17.5 with isoflurane, and the uterine horns were exposed by way of a laparotomy. Saline solution containing the expression plasmid of interest (2 mg/ml) together with the dye Fast Green (0.3 mg/ml; Sigma-Aldrich, Saint Louis, MO) was injected (1--2 μl) through the uterine wall into one of the lateral ventricles of the embryos. The embryo\'s head was electroporated by tweezer-type circular electrodes across the uterus wall, and five electrical pulses (50 V, 50 ms duration at 100 ms intervals) were delivered with a square-wave electroporation generator (model ECM 830, BTX Inc.). The uterine horns were then returned to the abdominal cavity, the wall and skin were sutured, and the embryos continued normal development. Control embryos were electroporated with the tdTomato construct together with the GFP construct (1:2 ratio), and experimental embryos were electroporated with DynII^K44A^ or PXN-shRNA (both sequence C and D) (see also Supplemental Materials), control scramble-shRNA, and the shRNA-resistant construct (PXN-shRNA-R), each in addition to the tdTomato construct. Control and experimental E20 embryos were obtained from the same litter and the injections were always made into the left and right ventricles, respectively, for later identification. Maximum intensities of the z-projection of tile images (20 µm thickness) were attained from spinning-disk confocal microscopy (Zeiss). Animal protocols were approved by the Animal Care and Use Committee of Academia Sinica.

Membrane floatation assay {#s4-14}
-------------------------

Dissected embryonic rat brain and heart at E17.5 were sonicated (four cycles of 20 s on and 10 s off) and mixed with 90% (w/w) sucrose to a final concentration of 45% sucrose in detergent-free lysis buffer (20 mM Tris-HCl, 5 mM MgCl~2~ and 1 mM DTT with Complete protease inhibitor). Samples (1.5 ml) were overlaid with 1.5 ml of 35% sucrose and 9 ml of 5% sucrose and centrifuged at 175,000 x *g* for 18 hr at 4°C. Fractions (300 μl each) were collected from the top and subjected to immunoblot analysis.

Statistical analysis {#s4-15}
--------------------

To choose the statistical test for comparisons between two datasets, we first examined whether the data in each set was normally distributed using a Jarque-Bera test. A *t* test was used for normally distributed datasets. One-way ANOVA followed by a Dunnett's post hoc *test* was used for comparisons involving multiple datasets.
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Major datasets {#s14}
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The following dataset was generated:

Chang TYChen CChang YCLu CHLee MLu STWang DYWang AGuo CLCheng PL2017Substrate stiffness-dependent gene expression profile for cortical neurons<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE102350>Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE102350)
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![Images of hippocampal neuronsunder differing culture conditionsfor 5 or 16 hr.\
(**A**) Bright-field images of hippocampal neurons cultured on coverslips (glass) coated under differing conditions for 5 or 16 hr, as indicated. (**B**) Images of neurons grown on 0.1 kPa gels or coverslips with varied coatings for 5 hr, stained for F-actin (phalloidin; red), microtubules (anti-Tuj-1; green), and nuclei (DAPI; blue). Asterisks mark cells with no lamellipodial protrusions. Arrows mark neurite-bearing neurons.](elife-31101-app1-fig1){#app1fig1}

![Proposed model for the biphasic behavior in neuronal morphogenesis (related to [Figure 3](#fig3){ref-type="fig"}).\
(**A**) The probability of segmentation depends on a 'P' factor that can bind to both endocytosis and adhesion complexes. When bound to the former, P factor enhances endocytosis and cells activate Rac1 and expression of factors required for the endocytic machinery (including P factor itself), providing a positive feedback that is modulated by substrate softness to accelerate segmentation. On stiff substrates, P factor is sequestered to cell-substrate adhesions, promoting a low-endocytosis and non-segmentable state. (**B**) Numerical simulations show that, based on the proposed model, cells can form a bistable switch between a high (Red line) and a low (Blue line) endocytosis state, dependent on the substrate modulus. (**C**) Numerical results show that the probability of segmentation depends on the substrate modulus and endocytic activity. (**D**) Numerical results show delayed onset of lamellipodium segmentation in cells grown on rigid substrates. For (**B--D**), see below model for details and parameters.](elife-31101-app1-fig2){#app1fig2}

![Active Integrin β1 staining of neurons grown on 0.1 kPa or 20 kPa gels.\
Right panel shows representative images of neuronal cultures stained with antibody specific against activated integrin β1 at the 16 hr time points after cell plating. Scale bar: 5 μm. Dot plot: quantification for puncta density of activated integrin 1 (n = 23--43 cells each, \*\*\*p\<0.001; *t* test).](elife-31101-app1-fig3){#app1fig3}

Basic assumptions of our model {#s8}
==============================

To construct our model, we made the following assumptions: (a) There is a common factor (hereafter referred to as the 'P factor') that increases the probability of segmentation (and hence neurite formation); (b) Both adhesion (for cell substrates) and endocytosis complexes bind to the P factor; (c) Most P factors are sequestered to either the adhesion or the endocytosis complexes; (d) Association of P factor with the endocytosis complex enhances endocytosis, by which cells can up-regulate the activation of Rac1 and the expression of endocytosis-related molecules (including P factor); (e) Increasing substrate stiffness enhances cell-substrate adhesion, thereby sequestering P factor from binding to the endocytosis complex and down-regulating the endocytic rate; (f) Expression levels of P factor and the endocytic machinery are co-regulated; and (g) The probability of segmentation depends on Rac1 activity.

To simplify our analysis, we grouped the endocytic complex (or machinery) and the adhesion complex (or machinery) into single entities denoted as X and Y, respectively. Because we assumed that the expression of P factor and the endocytic machinery is co-regulated, we set the total expression level of P factor \[*P~Total~*\] (represented by the concentration inside the cell) as being proportional to the total expression level of X \[*X~Total~*\] according to *P~Total~* ≈ e~PX~ × *X~Total~*, where *e~PX~* is a constant.

The chemical balance between the association and dissociation of P factor with X and Y follows:$$\begin{matrix}
 & {\lbrack P\rbrack + \lbrack X\rbrack\ \overset{K_{px}}{\longrightarrow}\lbrack PX\rbrack,} \\
 & {\lbrack PX\rbrack\ \overset{K_{px\_ diss}}{\longrightarrow}\lbrack P\rbrack + \lbrack X\rbrack.} \\
\end{matrix}$$$$\begin{matrix}
 & {\lbrack P\rbrack + \lbrack Y\rbrack\ \overset{K_{py}}{\longrightarrow}\lbrack PY\rbrack,} \\
 & {\lbrack PY\rbrack\ \overset{K_{py\_ diss}}{\longrightarrow}\lbrack P\rbrack + \lbrack Y\rbrack.} \\
\end{matrix}$$

with the constraint \[*PX*\] + \[*PY*\] + \[*P*\] = \[*P~Total~*\], \[*PX*\] + \[*X*\] = \[*X~Total~*\], and \[*PY*\] + \[*Y*\] = \[*Y~Total~*\], where \[*P~Total~*\], \[*X~Total~*\], and \[*Y~Total~*\] are the total expression levels of P factor, the adhesion complex machinery, and the endocytosis complex machinery, respectively. We assumed that most P factors are sequestered to either the endocytosis or the adhesion complex, and free-form P factor is limited (i.e., \[*P*\]\<\<1). As such, the quasi-steady state concentration of *PX* and *PY* can be estimated as:$$\begin{matrix}
 & {\lbrack PX\rbrack = {\frac{k_{px}\lbrack P\rbrack\lbrack X_{Total}\rbrack}{k_{px\_ diss} + k_{px}\lbrack P\rbrack} \approx k_{px}k_{px\_ diss}^{- 1}\lbrack P\rbrack\lbrack X_{Total}\rbrack,}} \\
 & {\lbrack PY\rbrack = {\frac{k_{py}\lbrack P\rbrack\lbrack Y_{Total}\rbrack}{k_{py\_ diss} + k_{py}\lbrack P\rbrack} \approx k_{py}k_{py\_ diss}^{- 1}\lbrack P\rbrack\lbrack Y_{Total}\rbrack}} \\
\end{matrix}$$

Consequently, we have:$$\begin{array}{l}
{\lbrack P\rbrack \approx {\frac{\lbrack P_{Total}\rbrack}{1 + k_{py}k_{py\_ diss}^{- 1}\lbrack Y_{Total}\rbrack + k_{px}k_{px\_ diss}^{- 1}\lbrack X_{Total}\rbrack},}} \\
{\rightarrow\lbrack PX\rbrack \approx {\frac{k_{px}k_{px\_ diss}^{- 1}e_{PX}\lbrack X_{Total}\rbrack^{2}}{1 + k_{py}k_{py\_ diss}^{- 1}\lbrack Y_{Total}\rbrack + k_{px}k_{px\_ diss}^{- 1}\lbrack X_{Total}\rbrack}.}} \\
\end{array}$$

For simplicity, we further assumed that the endocytic rate is proportional to \[*PX*\].$$Endocytic\ rate\  \propto \lbrack PX\rbrack$$

Analysis of two-state behavior {#s9}
==============================

Next, we considered the equation for endocytosis-induced up-regulation of the expression of P factor and the endocytic machinery. We used a simple approach in that the endocytosis-induced up-regulation follows Michaelis--Menten kinetics ([@bib50]). Based on the assumption that the endocytic rate is proportional to \[*PX*\] ([Equation (5)](#equ5){ref-type="disp-formula"}, we have:$$\frac{d\lbrack X_{Total}\rbrack}{dt} = k_{deg}\left( {X_{0} + X_{up}\frac{\lbrack PX\rbrack}{PX_{T} + \lbrack PX\rbrack} - \lbrack X_{Total}\rbrack} \right),$$

where *k*~deg~ is the degradation rate, *X*~0~ is the baseline expression in the absence of endocytosis-induced up-regulation, *X~up~* is the efficacy for endocytosis-induced up-regulation. Michaelis--Menten kinetics use a constant *PX~T~* as the threshold for \[*PX*\] to reach half the maximum level of up-regulation. Substituting [Equation (4)](#equ4){ref-type="disp-formula"} into [Equation (6)](#equ6){ref-type="disp-formula"}, we have:$$\frac{d\lbrack X_{Total}\rbrack}{k_{\deg}dt} = X_{0} + {\frac{X_{up}k_{up}k_{px\_ diss}^{- 1}e_{PX}\lbrack X_{Total}\rbrack^{2}}{PX_{T}\left( {1 + k_{py}k_{py_{d}iss}^{- 1}\lbrack Y_{Total}\rbrack + k_{px}k_{px\_ diss}^{- 1}\lbrack X_{Total}\rbrack} \right) + k_{px}k_{px\_ diss}e_{PX}\lbrack X_{Total}\rbrack^{2}} - \lbrack X_{Total}\rbrack.}$$

We further simplified [Equation (7)](#equ7){ref-type="disp-formula"} by setting *t* = *k*~deg~*t*, *β*= *e~PX~X*~0~/*PX~T~*, *α* = *e~PX~X~up~*/*PX~T~*, *x* = *e~PX~*\[*X~Total~*\]/*PX~T~*, and *y* = *e~PX~*(1 + *k~py~* \[*Y~Total~*\]/*k~py_diss~*)/(*k~px~PX~T~*/*k~px_diss~*) and obtained:$$\frac{dx}{d\tau} = \beta + \frac{\alpha x^{2}}{y + x + x^{2}} - x,$$$$Endocytosis\ rate\  \propto \lbrack PX\rbrack \approx PX_{T}\frac{x^{2}}{x + y} \propto \frac{x^{2}}{x + y}.$$

Here, variable *x* is related to the expression level of the endocytic machinery (including P factor). Variable *y* is related to cell-substrate adhesion and increases with substrate stiffness. For simplicity, we approximated *y* with a linear dependence on the substrate modulus; namely, *y* = *y*~0~ + *y*~1~×substrate modulus, where *y*~0~ and *y*~1~ are constants. The steady-state solutions of [Equation (8)](#equ8){ref-type="disp-formula"} can be found by solving its null-clines in the *x-y* plane, which read:$$y = \frac{\alpha x^{2}}{x - \beta} - x(x + 1).$$

An example of [Equation (10)](#equ10){ref-type="disp-formula"} is illustrated in [Appendix 1---figure 2B--D](#app1fig2){ref-type="fig"}, in which we use a linear relationship to link the substrate modulus with the variable *y* (i.e., *y* = *y*~0~ + *y*~1~ × substrate modulus) and to set the endocytic rate as a function of *x* and *y* ([Equation (9)](#equ9){ref-type="disp-formula"}). Analysis of [Equation (10)](#equ10){ref-type="disp-formula"} revealed that for a given *y*, two stable steady-state solutions of *x* could coexist (the two solid lines in Figure S6B) with one unstable transition-state solution (the dotted line in Figure S6B), provided that the following criterion is satisfied:$$(\alpha - 2\beta - 1)^{3} \geq 27\alpha\beta^{2}$$

Under such a condition, cells possess the ability to perform a bistable switch between a high-*x* state and a low-*x* state for a given *y* (i.e., substrate stiffness). Here, the high-*x* state corresponds to the endocytosis-dominant state where the cells exhibit a higher endocytic rate, higher Rac1 activation, and higher expression of the endocytic machinery (including P factor). In comparison, the low-*x* state corresponds to the adhesion-dominant state with lower Rac1 activation and lower expression of the endocytic machinery. For convenience, hereafter we define *S*(*x*, *y*) as the state for a given set of (*x*, *y*). Furthermore, for any given *y*, we define *S~end~*(*x~end~*(*y*), *y*) as the corresponding endocytosis-dominant state, with *x~end~*(*y*) as the steady-state solution from [Equation (10)](#equ10){ref-type="disp-formula"}. Likewise, we define *S~adh~*(*x~adh~*(*y*), *y*) as the adhesion-dominant state for a given *y*, with *x~adh~*(*y*) as the steady-state solution. Similarly, *S~tx~*(*x~tx~*(*y*), *y*) defines the transition state for a given *y*, with *x~tx~*(*y*) as the steady-state solution.

Statistics of two-state behavior {#s10}
================================

The distribution of the proposed two states at a given substrate modulus (i.e., *y*) can be estimated by rewriting [Equation (8)](#equ8){ref-type="disp-formula"} into a Langevin equation followed by adopting a free energy approach ([@bib45]; [@bib51]). The 'free energy' is then used to estimate the probability of finding one cell at a given state. Furthermore, the free energy can be used to estimate the rate at which the cells switch from one state to another. Specifically, we approximated [Equation (8)](#equ8){ref-type="disp-formula"} as the derivative of a free energy, *F*(*x, y*), and added a time-dependent Gaussian white noise *η*of width *D* to the system:$$\frac{dx}{d\tau} = \beta + \frac{\alpha x^{2}}{y + x + x^{2}} - x + \eta(\tau) = - \frac{dF(x,y)}{dx} + \eta(\tau),$$

where$$\begin{matrix}
 & {\left\langle {\eta(\tau)\eta(\tau^{\prime})} \right\rangle = D\delta(\tau - \tau^{\prime})} \\
 & {\left\langle {\eta(\tau)} \right\rangle = 0} \\
\end{matrix}$$$$\begin{matrix}
{F(x,y) =} & {\!\!\!\!{C - (\alpha + \beta)x - \frac{x^{2}}{2} + \frac{\alpha}{2}{In}(y + x + x^{2}) + \frac{\alpha}{2} \times}} \\
 & \left\{ \begin{matrix}
{\frac{(y - 1/2)}{\sqrt{\left| {y - 1/4} \right|}}{In}\left( \frac{x + 1/2 - \sqrt{\left| {y - 1/4} \right|}}{x + 1/2 + \sqrt{\left| {y - 1/4} \right|}} \right)} & {y < 1/4} & \\
\frac{1}{x + 1/2} & {y = 1/4,} & \\
{\frac{(y - 1/2)}{\sqrt{\left| {y - 1/4} \right|}}{tan^{- 1}}\left( \frac{x + 1/2}{\left| {y - 1/4} \right|} \right)} & {y > 1/4} & \\
\end{matrix} \right. \\
\end{matrix}$$

with *C* as an integral constant. The probability of finding one cell at a state *S*(*x*, *y*), denoted as *f*(*x*, *y*), is then specified by the free energy as:$$f(x,y) \propto \,\exp\lbrack F(x,y)/D\rbrack,$$

or$$f(x,y) = \frac{e^{- F(x,y)/D}}{\int{dxe^{- F(x,y)/D}}}.$$

Note that in Eqn. \[16\], *x* does not need to be the steady-state solution from [Equation (10)](#equ10){ref-type="disp-formula"}. For the bistable regime where cells are allowed to select one of the steady states at a given *y* (provided that [Equation (11)](#equ11){ref-type="disp-formula"} is satisfied) or switch from one state to another, the rate at which the switch occurs can be estimated by Transition State Theory, Eyring theory, Arrhenius' law, or Kramers' law ([@bib34]; [@bib76]). For instance, for a cell in the endocytosis-dominant state, the average rate at which it switches to the adhesion-dominant state, *k~end\ →\ adh~*, can be calculated by the mean first passage time by which the cell moves from the endocytosis-dominant state *S~end~*(*x~end~*(*y*), *y*) to the transition state *S~tx~*(*x~tx~*(*y*), *y*), *τ~end\ →\ tx~*, in the free energy landscape *F*(*x*, *y*). Likewise, the average rate at which the cell switches from the adhesion-dominant state to the endocytosis-dominant state, *k~adh\ →\ end~*, can be calculated by the mean first passage time *τα~dh\ →\ tx~*. Following Transition State Theory, Eyring theory, Arrhenius' law, or Kramers' law ([@bib34]; Wodkiewicz, 1984), we establish the switch rate at a given *y* as:$$\begin{array}{l}
{k_{end}\rightarrow_{adh}(y) \sim k_{0} \times {exp}\lbrack(F(x_{end}(y),y) - F(x_{tx}(y),y))/D\rbrack,} \\
{k_{adh}\rightarrow_{end}(y) \sim k_{0} \times {exp}\lbrack(F(x_{adh}(y),y) - F(x_{tx}(y),y))/D\rbrack} \\
\end{array}$$

where *k*~0~ is a constant.

Segmentation rate in the two-state system {#s11}
=========================================

In our model, we assumed that the probability of segmentation depends on Rac1 activity, which is primarily induced by endocytosis. To estimate the segmentation rate, hereafter defined as *k~s~*(*x*, *y*), we approximated it as being proportional to the endocytic rate [Equations (5 and 9)](#equ5 equ9){ref-type="disp-formula"}, namely:$$Segmentation\ rate\ k_{s}(x,y) \propto Endocytosis\ rate\  \sim \frac{x^{2}}{x + y}.$$

Examples of the segmentation rates from [Equation (18)](#equ18){ref-type="disp-formula"} are illustrated in Figure S6C, where the rates for the endocytosis-dominant and adhesion-dominant states are plotted. For a given *y*, the expected rate of segmentation in a population of cells was estimated as:$$\begin{matrix}
{Expected\ Segmentation\ rate\ \left\langle {k_{s}(y)} \right\rangle} & {\sim \frac{f(x_{adh}(y)){\frac{x_{adh}^{2}}{x_{adh} + y} + f(x_{end}(y))\frac{x_{end}^{2}}{x_{end} + y}}}{f(x_{adh}(y),y) + f(x_{end}(y),y)}} \\
 & {= {\frac{e^{- F(x_{adh}(y),y)/D}{\frac{x_{adh}^{2}}{x_{adh} + y} + e^{- F(x_{end}(y),y)/D}\frac{x_{end}^{2}}{x_{end} + y}}}{e^{- F(x_{adh}(y),y)/D} + e^{- F(x_{end}(y),y)/D}}.}} \\
\end{matrix}$$

Segmentation dynamics in the two-state system {#s12}
=============================================

Finally, we estimated the dynamics of a population of cells that progressively switched to the segmented state. To do so, we assumed that cells were initially in the adhesion-dominant state, and defined the density of cells in the adhesion-dominant state as *n~adh~*(*τ*) for a given time *τ*, the density of cells in the endocytosis-dominant state as *n~end~*(*τ*), and the density of cells that formed segments as *n~seg~*(*τ*), with the following constraints: *n~adh~*(0) = 1, *n~end~*(0) = 0, and *n~adh~*(*τ*)+*n~end~*(*τ*)+*n~seg~*(*τ*)=1. The dynamics for these cells are as follows:$$\begin{matrix}
\frac{dn_{adh}}{d\tau} & {= - k_{s}(x_{adh}(y),y)n_{adh} - k_{adh\rightarrow end}(y)n_{adh} + k_{end\rightarrow adh}(y)n_{end},} \\
\frac{dn_{end}}{d\tau} & {= - k_{s}(x_{end}(y),y)n_{end} + k_{adh\rightarrow end}(y)n_{adh} + k_{end\rightarrow adh}(y)n_{end},} \\
\frac{dn_{seg}}{d\tau} & {= - k_{s}(x_{adh}(y),y)n_{adh} + k_{s}(x_{end}(y),y)n_{end}.} \\
\end{matrix}$$

Examples of the segmentation dynamics in a population of cells are illustrated in Figure S6D, where the contributions from cells in the endocytosis-dominant or the adhesion-dominant states is plotted separately.

Parameters used in the figures {#s13}
==============================

To simulate the segmentation dynamics illustrated in [Appendix 1---figure 2](#app1fig2){ref-type="fig"}, we set *α* = 2.5, *β* = 0.1, *k*~0~ = 1, *D* = 1, and *y* = 0.7 + 10^−5^ × substrate rigidity, and used [Equations (10 , 17 , 18 and 20)](#equ10 equ17 equ18 equ20){ref-type="disp-formula"}.
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###### Gene ontology analysis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                               5 hr                                        16 hr                                                                              
  ---------------------------- ------------------------------------------- ----------------------------------- ---------------------------------------------- -------------------------
  0.1 kPa                      *Receptor-mediated endocytosis*             *Cell differentiation*                                                             

  \*\*                         receptor-mediated endocytosis               \*                                  forebrain neuron fate commitment               

  \*                           endocytic adaptor activity                  *Cytoskeleton*                                                                     

  \*                           clathrin adaptor activity                   \*\*                                intermediate filament binding                  

  \*\*                         regulation of receptor recycling            \*                                  protein localization to cytoskeleton           

  \*\*\*                       positive regulation of\                     \*                                  protein localization to\                       
                               receptor recycling                                                              microtubule cytoskeleton                       

  *Vesicle transport*          *Cell aggregation*                                                                                                             

  \*\*                         endosomal vesicle fusion                    \*                                  cell aggregation                               

  \*                           vesicle-mediated transport                  GTPase signaling pathway                                                           

  \*\*\*                       response to lipid                           \*\*                                G-protein coupled neurotensin\                 
                                                                                                               receptor activity                              

  0.1 kPa                      *External stimulus*                                                                                                            

  \*\*\*                       response to external stimulus                                                                                                  

  \*\*                         regulation of cell-substrate\                                                                                                  
                               adhesion                                                                                                                       

  \*                           laminin-1 binding                                                                                                              

  *Neuronal development*                                                                                                                                      

  \*                           axon midline choice\                                                                                                           
                               point recognition                                                                                                              

  \*\*                         regulation of long term\                                                                                                       
                               synaptic depression                                                                                                            

  *Cell polarity*                                                                                                                                             

  \*                           maintenance of cell polarity                                                                                                   

  \*                           positive regulation of Wnt\                                                                                                    
                               signaling pathway, planar\                                                                                                     
                               cell polarity pathway                                                                                                          

  0.1 kPa                      *Cell migration*                                                                                                               

  \*\*                         regulation of cell migration                                                                                                   

  \*                           positive regulation of cell migration                                                                                          

  \*\*                         regulation of cell motility                                                                                                    

  \*                           positive regulation of cell motility                                                                                           

  *GTPase signaling pathway*                                                                                                                                  

  \*\*                         regulation of Rho-dependent\                                                                                                   
                               protein serine/threonine\                                                                                                      
                               kinase activity                                                                                                                

  \*                           adenylate cyclase-activating\                                                                                                  
                               G-protein coupled receptor\                                                                                                    
                               signalling pathway                                                                                                             

  *Cytoskeleton*                                                                                                                                              

  \*                           neurofilament cytoskeleton                                                                                                     

  20 kPa                       *Nervous system development*                *Nervous system development*                                                       

  \*                           central nervous system development          \*                                  central nervous system\                        
                                                                                                               neuron development                             

  \*                           regulation of dendrite development          \*\*                                negative regulation of neurogenesis            

  \*\*                         regulation of neurogenesis                  \*                                  neuronal action potential propagation          

  \*\*                         regulation of nervous\                      \*\*                                regulation of neuron\                          
                               system development                                                              projection development                         

  \*                           pyramidal neuron development                \*                                  axon midline choice point recognition          

  \*                           cell projection                             \*                                  axon guidance receptor activity                

  \*\*                         internode region of axon                    *Signaling transduction*                                                           

  \*\*                         cellular developmental process              \*                                  protein kinase A signaling                     

  \*                           regulation of cell development              \*\*                                positive regulation of phosphatidylinositol\   
                                                                                                               3-kinase signalling                            

  20 kPa                       *Cell differentiation*                      \*\*\*                              second-messenger-mediated signaling            

  \*                           cell differentiation                        *Cell differentiation*                                                             

  \*                           pyramidal neuron differentiation            \*\*                                neuron fate commitment                         

  \*                           regulation of cell morphogenesis\           \*\*                                central nervous system\                        
                               involved in differentiation                                                     neuron differentiation                         

  *Vesicle transport*          \*\*                                        negative regulation of\                                                            
                                                                           neuron differentiation                                                             

  \*\*                         late endosome                               *Morphogenesis*                                                                    

  \*                           regulation of lipid transport               \*                                  cell morphogenesis                             

  *Cell migration*             \*                                          positive regulation of dendritic\                                                  
                                                                           spine morphogenesis                                                                

  20 kPa                       \*\*                                        locomotory behavior                 *Cell adhesion*                                

  \*                           negative regulation of\                     \*                                  response to mechanical stimulus                
                               neuron migration                                                                                                               

  *GTPase signaling pathway*   \*\*                                        extracellular matrix binding                                                       

  \*                           Rho guanyl-nucleotide\                      \*                                  positive regulation of\                        
                               exchange factor activity                                                        cell-substrate adhesion                        

  \*\*                         Rho protein signal transduction             \*\*                                laminin-1 binding                              

  \*                           positive regulation of adenylate cyclase\   \*\*\*\*                            positive regulation\                           
                               activity involved in G-protein coupled\                                         of cell adhesion                               
                               receptor signalling pathway                                                                                                    

  *Cytoskeleton*               \*\*                                        protein binding involved in\                                                       
                                                                           cell adhesion                                                                      

  \*                           regulation of actin\                        *Cell migration*                                                                   
                               cytoskeleton organization                                                                                                      

  20 kPa                       \*                                          regulation of actin\                \*\*                                           positive regulation of\
                                                                           filament-based process                                                             cell migration

                                                                           \*                                  negative regulation of cell adhesion\          
                                                                                                               involved in substrate-bound\                   
                                                                                                               cell migration                                 

                                                                           \*\*                                positive regulation of locomotion              

                                                                           *Neuronal regeneration*                                                            

                                                                           \*                                  negative regulation of\                        
                                                                                                               axon regeneration                              

                                                                           \*                                  negative regulation of\                        
                                                                                                               neuron projection regeneration                 

                                                                                                               Transport                                      

                                                                           \*\*                                regulation of transport                        

  20 kPa                                                                                                       *Cytoskeleton*                                 

                                                                           \*                                  actin filament binding                         

                                                                           \*\*                                actin filament bundle assembly                 

                               \*p\<0.05; \*\*p\<0.01;\                    \*                                  ruffle assembly                                
                               \*\*\*p\<0.001; \*\*\*\*p\<0.0001. t test                                                                                      
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### Microarray analysis and identification of substrate modulus-regulated genes in hippocampal neurons.

                        Gene symbol    Accession number                                                                  Gene name                                           0.1 kPa   1 kPa   20 kPa   Glass
  ------- ------------- -------------- --------------------------------------------------------------------------------- --------------------------------------------------- --------- ------- -------- -------
  5 hr                  *inhba*        NM_017128                                                                         inhibin beta-A                                      12.45     11.81   11.83    11.65
  ●       *cdc42bpa*    NM_053657      CDC42 binding protein kinase alpha                                                11.45                                               10.91     10.78   11.22    
          *ubr2*        NM_001178071   ubiquitin protein ligase E3 component n-recognin 2                                10.82                                               10.38     10.21   10.20    
          *mx1*         NM_173096      myxovirus (influenza virus) resistance 1                                          10.72                                               10.06     9.91    9.85     
  ●       *myo6*        XM_006226497   myosin VI (probe 1)                                                               10.58                                               10.03     9.96    10.40    
          *tagln2*      NM_001013127   transgelin 2                                                                      10.31                                               9.84      9.72    10.67    
          *gbp2*        NM_133624      guanylate binding protein 2, interferon-inducible                                 10.17                                               9.54      8.86    9.37     
          *col1a2*      NM_053356      collagen, type I, alpha 2                                                         10.14                                               9.53      9.45    10.45    
  5 hr                  *cxcl16*       NM_001017478                                                                      chemokine (C-X-C motif) ligand 16                   9.89      9.34    8.78     9.63
          *ifi27l2b*    NM_206846      interferon, alpha-inducible protein 27 like 2B                                    9.88                                                8.80      7.95    9.11     
          *bpifb1*      NM_001077680   BPI fold containing family B, member 1                                            9.84                                                8.73      8.44    7.44     
  ●       *pik3r1*      NM_013005      phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                           9.82                                                9.28      9.16    9.36     
          *sorcs3*      NM_001106367   sortilin-related VPS10 domain containing receptor 3                               9.76                                                8.86      8.74    9.57     
          *slc13a3*     NM_022866      solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3   9.55                                                9.14      8.94    8.41     
          *igf2*        NM_031511      insulin-like growth factor 2                                                      9.41                                                8.58      8.59    8.99     
          *mbp*         NM_001025291   myelin basic protein, transcript variant 1                                        9.40                                                8.33      8.59    8.31     
  5 hr    ●             *plvap*        NM_020086                                                                         plasmalemma vesicle associated protein              9.32      8.43    7.98     9.33
          *rsad2*       NM_138881      radical S-adenosyl methionine domain containing 2                                 9.30                                                8.82      8.11    9.19     
  ●       *dab2*        NM_024159      disabled 2, mitogen-responsive phosphoprotein                                     8.94                                                8.46      7.97    8.14     
          *isg15*       NM_001106700   ISG15 ubiquitin-like modifier                                                     8.83                                                8.17      7.24    7.91     
  ●       *myo6*        XM_006226497   myosin VI (probe 2)                                                               8.65                                                8.10      8.00    8.42     
  ●       *robo3*       NM_001108135   roundabout, axon guidance receptor, homolog 3 (Drosophila)                        8.49                                                7.81      7.56    6.89     
          *samd9l*      XM_001069386   sterile alpha motif domain containing 9-like                                      8.48                                                7.84      7.63    9.07     
          *nid1*        XM_213954      nidogen 1                                                                         8.10                                                7.02      7.06    7.65     
  5 hr    □             *nexn*         NM_139230                                                                         nexilin (F actin binding protein)                   7.91      6.72    6.90     7.15
          *calcr*       NM_053816      calcitonin receptor                                                               7.90                                                6.30      5.73    7.13     
          *irg1*        NM_001107282   immunoresponsive gene 1                                                           7.88                                                7.40      6.54    6.79     
          *lgals3bp*    NM_139096      lectin, galactoside-binding, soluble, 3 binding protein                           7.86                                                7.51      7.14    7.08     
          *ccl6*        NM_001004202   chemokine (C-C motif) ligand 6                                                    7.79                                                7.03      6.29    5.86     
          *aebp1*       NM_001100970   AE binding protein 1                                                              7.69                                                6.99      6.93    7.55     
          *tp53inp1*    NM_181084      tumor protein p53 inducible nuclear protein 1                                     7.63                                                7.32      7.01    7.55     
          *trpc3*       NM_021771      transient receptor potential cation channel, subfamily C, member 3                7.36                                                6.90      6.76    5.94     
  5 hr                  *oasl2*        NM_001009682                                                                      2\'-5\' oligoadenylate synthetase-like 2            7.33      6.69    6.20     6.39
          *nqo1*        NM_017000      NAD(P)H dehydrogenase, quinone 1                                                  7.33                                                6.87      6.55    6.70     
          *dst*         XM_006226778   dystonin                                                                          7.22                                                6.71      6.50    6.70     
  ●       *arap1*       XM_006223427   ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1                         6.97                                                6.45      6.30    6.55     
          *gcgr*        NM_172091      glucagon receptor                                                                 6.94                                                6.49      5.55    5.99     
  5 hr    ●             *arhgef19*     NM_001108692                                                                      Rho guanine nucleotide exchange factor (GEF) 19     8.96      9.30    9.59     8.92
  ●       *map2k6*      NM_053703      mitogen-activated protein kinase kinase 6                                         8.75                                                9.22      9.37    8.83     
  ●       *gpr56*       NM_152242      G protein-coupled receptor 56                                                     8.72                                                9.00      9.40    8.67     
          *tst*         NM_012808      thiosulfate sulfurtransferase                                                     8.66                                                9.26      9.29    9.12     
          *six5*        XM_003753221   SIX homeobox 5                                                                    7.96                                                8.63      8.64    8.21     
          *mbp*         NM_001025289   myelin basic protein, transcript variant 6                                        7.89                                                8.46      8.58    8.18     
          *atp7a*       NM_052803      ATPase, Cu++ transporting, alpha polypeptide                                      7.66                                                8.29      8.85    7.95     
          *cyb561a3*    NM_001014164   cytochrome b561 family, member A3                                                 6.97                                                7.53      7.65    7.23     
  5 hr                  *dnah8*        XM_001079004                                                                      dynein, axonemal, heavy chain 8                     6.71      7.52    7.43     7.01
          *scrt2*       NM_001191905   scratch family zinc finger 2                                                      6.04                                                6.36      6.64    6.18     
          *crhr1*       NM_030999      corticotropin releasing hormone receptor 1                                        5.95                                                6.42      6.60    5.91     
          *bmx*         NM_001109016   BMX non-receptor tyrosine kinase                                                  5.95                                                6.54      6.56    6.77     
  ○       *celsr1*      XM_006242168   cadherin, EGF LAG seven-pass G-type receptor 1                                    5.88                                                6.47      6.60    6.60     
          *timp3*       NM_012886      TIMP metallopeptidase inhibitor 3                                                 5.77                                                6.03      6.47    6.89     
  ●       *prex1*       NM_001135718   phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1          5.48                                                5.89      6.07    5.64     
          *clcn2*       NM_017137      chloride channel, voltage-sensitive 2                                             5.38                                                5.84      6.09    5.39     
  5 hr    ●             *crebl2*       NM_001015027                                                                      cAMP responsive element binding protein-like 2      5.15      5.45    5.79     5.25
          *neurog3*     NM_021700      neurogenin 3                                                                      4.80                                                5.18      5.43    5.57     
          *fam161a*     NM_001013876   family with sequence similarity 161, member A                                     4.80                                                5.34      5.60    5.29     
  16 hr                 *snx10*        NM_001013085                                                                      sorting nexin 10                                    9.69      9.49    8.86     9.23
          *col2a1*      NM_012929      collagen, type II, alpha 1                                                        9.69                                                9.23      8.91    9.29     
          *ftcd*        NM_053567      formimidoyltransferase cyclodeaminase                                             9.67                                                9.13      8.68    9.28     
          *tfap2c*      NM_201420      transcription factor AP-2 gamma                                                   8.27                                                8.14      7.67    8.29     
          *ntsr2*       NM_022695      neurotensin receptor 2                                                            7.65                                                7.25      6.98    7.37     
  ○       *itgb4*       NM_013180      integrin, beta 4                                                                  7.34                                                6.98      6.75    6.68     
  16 hr                 *caprin1*      NM_001012185                                                                      cell cycle associated protein 1                     11.46     11.53   12.08    11.56
          *inhba*       NM_017128      inhibin beta-A                                                                    11.31                                               11.91     12.45   11.98    
  ●       *robo2*       NM_032106      roundabout, axon guidance receptor, homolog 2 (Drosophila)                        11.03                                               11.29     11.69   11.32    
          *mkks*        NM_001008353   McKusick-Kaufman syndrome                                                         10.70                                               11.05     11.29   11.30    
          *itpr1*       NM_001007235   inositol 1,4,5-trisphosphate receptor, type 1                                     10.32                                               10.80     11.22   10.83    
          *igf1*        NM_001082479   insulin-like growth factor 1                                                      10.21                                               10.61     11.53   10.35    
          *aif1*        NM_017196      allograft inflammatory factor 1                                                   9.82                                                10.34     10.52   10.52    
          *gucy1a3*     XM_006232518   guanylate cyclase 1, soluble, alpha 3                                             9.75                                                9.91      10.42   9.96     
          *cnksr2*      NM_021686      connector enhancer of kinase suppressor of Ras 2                                  9.73                                                9.88      10.32   9.73     
  16 hr                 *ptpn6*        NM_053908                                                                         protein tyrosine phosphatase, non-receptor type 6   9.67      10.15   10.32    10.18
          *lcp1*        NM_001012044   lymphocyte cytosolic protein 1                                                    9.13                                                9.64      10.14   9.39     
          *olig2*       NM_001100557   oligodendrocyte lineage transcription factor 2                                    9.10                                                9.56      10.61   9.83     
          *jag1*        NM_019147      jagged 1                                                                          9.05                                                9.21      9.69    9.27     
          *fst*         NM_012561      follistatin                                                                       8.99                                                9.65      10.05   9.36     
          *gucy1b3*     NM_012769      guanylate cyclase 1, soluble, beta 3                                              8.98                                                9.08      9.69    9.30     
          *igf1*        NM_001082479   insulin-like growth factor 1                                                      8.86                                                9.28      10.15   9.08     
          *olig1*       NM_021770      oligodendrocyte transcription factor 1                                            8.85                                                9.32      9.81    9.82     
          *npy1r*       NM_001113357   neuropeptide Y receptor Y1                                                        8.61                                                9.28      9.76    9.28     
  16 hr                 *tnf*          NM_012675                                                                         tumor necrosis factor                               8.57      8.95    9.49     8.71
  ○       *cdh11*       NM_053392      cadherin 11                                                                       8.33                                                8.59      9.06    8.64     
  ○       *nrcam*       NM_013150      neuronal cell adhesion molecule                                                   8.28                                                8.92      8.91    8.78     
          *spp1*        NM_012881      secreted phosphoprotein 1                                                         8.20                                                9.52      11.57   8.78     
          *ccl4*        NM_053858      chemokine (C-C motif) ligand 4                                                    8.16                                                8.94      9.37    8.52     
          *nid1*        XM_213954      nidogen 1                                                                         7.85                                                7.97      8.86    9.12     
          *cd53*        NM_012523      Cd53 molecule                                                                     7.83                                                8.44      9.00    8.13     
  ●       *ntf3*        NM_031073      neurotrophin 3                                                                    7.78                                                7.87      8.45    7.96     
          *il18*        NM_019165      interleukin 18                                                                    7.28                                                8.07      8.42    8.09     
  16 hr                 *fcgr3a*       NM_207603                                                                         Fc fragment of IgG, low affinity IIIa, receptor     7.23      7.91    8.71     7.77
  ●       *cdk6*        NM_001191861   cyclin-dependent kinase 6                                                         6.81                                                7.11      7.73    7.57     
  ○       *itgb2*       NM_001037780   integrin, beta 2                                                                  6.63                                                7.09      7.61    6.91     
          *ly86*        NM_001106128   lymphocyte antigen 86(probe1)                                                     6.45                                                7.29      7.53    7.22     
          *ly96*        NM_001024279   lymphocyte antigen 96                                                             6.02                                                6.39      6.70    6.48     
          *ccr5*        NM_053960      chemokine (C-C motif) receptor 5                                                  5.96                                                6.28      6.72    5.83     
          *ptprc*       NM_138507      protein tyrosine phosphatase, receptor type, C                                    5.95                                                6.82      7.46    6.54     
          *ly86*        NM_001106128   lymphocyte antigen 86(probe 2)                                                    5.94                                                6.79      7.00    6.86     
          *loc360228*   NM_001003706   WDNM1 homolog                                                                     4.40                                                6.20      6.02    5.80     

○ Adhesion.

● Endocytosis.

● Neuritogenesis-related signaling.

□ Cytoskeleton.

10.7554/eLife.31101.029

###### Paxillin-associating protein identified by liquid chromatography-tandem mass spectrometry.

  Category                 Protein ID                                                                  Score   MW    MWobs
  ------------------------ --------------------------------------------------------------------------- ------- ----- -------
  Endocytosis              clathrin heavy chain 1                                                      68      190   190
                           dynamin-1-like protein isoform X17                                          84      80    80
  Adhesion                 talin-1                                                                     159     270   270
  Cytoskeleton             drebrin isoform X3                                                          90      72    120
  dynamics                 alpha-internexin                                                            70      56    60
                           citron Rho-interacting kinase                                               63      235   270
                           protein unc-45 homolog B isoform X1                                         243     103   105
  Transcription/           matrin-3                                                                    152     94    120
  Translation              elongation factor 1-alpha 1                                                 94      50    49
                           eukaryotic translation initiation factor 3 subunit A                        114     163   180
                           eukaryotic translation initiation factor 3 subunit B                        57      90    120
                           eukaryotic translation initiation factor 3, subunit 6 interacting protein   51      66    65
                           heterogeneous nuclear ribonucleoprotein M, isoform X2                       98      64    75
                           AT-rich interactive domain-containing protein 1B isoform X3, partial        58      58    63
                           heterogeneous nuclear ribonucleoprotein A2/B1                               181     38    37
  Protein quality          heat shock protein 60 kDa precrusor                                         171     61    60
  control                  heat shock cognate 71 kDa protein                                           182     71    75
                           heat shock protein 90 kDa alpha, class B member 1                           222     83    95
                           T-complex protein 1 subunit alpha                                           79      60    60
                           T-complex protein 1 subunit gamma                                           79      60    60
                           protein unc-45 homolog B isoform X1                                         243     103   105
                           stress-70 protein                                                           70      74    75
  Signaling transduction   calcium/calmodulin-dependent protein kinase II, beta 3 isoform              67      65    65
  DNA repair               fanconi anemia group C protien homolog                                      73      64    60
  Metabolism               glyceraldehyde-3-phosphate dehydrogenase                                    192     36    36
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Shen

Kang
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Paxillin facilitates timely neurite initiation on soft-substrate environments by interacting with the endocytic machinery\" for consideration by *eLife*. Your article has been favorably evaluated by Marianne Bronner (Senior Editor) and three reviewers, one of whom, Kang Shen, is a member of our Board of Reviewing Editors. The following individual involved in review of your submission has agreed to reveal her identity: Bianxiao Cui (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Chang et al. investigated an interesting observation that embryonic neurons cultured on the soft substrate grow out neurites much earlier. Through pharmacological inhibitor treatments, genetic manipulations (in cells and in animals), and biochemical probes, the authors established a strong correlation between early neurite outgrowth and the endocytosis process. In particular, the authors identified a crucial protein player paxillin that mediates the correlation. Paxillin is widely known for its role in focal adhesion. Using co-IP and other methods, this paper demonstrated that paxillin also participates in clathrin-mediated endocytosis by interacting with CIP4, a previously unknown role for paxillin. Their evidence suggests that two processes (focal adhesion and endocytosis) compete for paxillin, depending on the substrate rigidity. These discoveries led to an interesting hypothesis that Paxillin acts as a switch between adhesion and endocytosis. The manuscript also contains a large of amount of well-carried-out work, and the evidence is very convincing. Overall, this manuscript is of high quality and the reviewers support the potential publication of this manuscript in *eLife* given that the authors can address the issues raised below. Most of the issues can be dealt with by rewriting. However, appropriate experimental data can also be added if they help to clarify the issues.

Essential revisions:

1\) We are not completely convinced that paxillin functions as a \"molecular switch\" -- the authors do not perform experiments where they manipulate paxillin\'s binding state to endocytic or adhesion molecules and observe an ability to switch between neurite outgrowth/no outgrowth. Indeed, overexpression of CIP4 did not affect neural migration ([Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}) although the polarity of neurons was not quantified here. As part of the argument for the \"molecular switch\" model, the authors suggest that paxillin binds preferentially with endocytic factors when neurons are grown on soft cultures to initiate neurite outgrowth, whereas it binds preferentially with adhesion factors when neurons are grown on stiff cultures. This conclusion is drawn from colocalization in immunostaining in [Figures 3D-3F](#fig3){ref-type="fig"}, as well as co-IP in [Figure 4A](#fig4){ref-type="fig"}. However, the expression levels of endocytic and adhesion factors also change depending on the stiffness of the substrate -- could the increased localization of paxillin with vinculin and p-FAK on stiff substrates just reflect an increase in expression?

2\) Furthermore, is there evidence that such a substrate-based switch between neurite outgrowth and non-growth is physiologically relevant? Are there tissues in the developing brain or embryo with high enough stiffness to trigger the adhesion \"switch\" in paxillin (2016 AFM showed 400 Pa in retinotectal system)?

3\) The evidence for vinculin vs. CIP4 competitive binding to paxillin could use more validation -- it appears that vinculin is capable of binding to the LD1 domain, and the authors find it necessary to use a highly truncated paxillin to disrupt binding of both vinculin and CIP4.

Minor points \[abridged\]:

\[\...\] 8) Since this manuscript suggests that paxillin facilitates neurite growth by interacting with CIP4 and participating in endocytosis, it implies that CIP4 also has a positive role in neurite growth. However, a previous published paper (cited below) suggests that CIP4 inhibits neurite outgrowth, a conclusion that is opposite of this manuscript. All work done in the previous was performed on glass substrates. Is it possible that CIP4 also functions differently in substrates of different softness? Can the authors reconcile their conclusion with the previous study? \"The F-BAR Protein CIP4 Inhibits Neurite Formation by Producing Lamellipodial Protrusions\"Current Biology 22, 494-501, March 20, 2012.

10.7554/eLife.31101.034

Author response

> Essential revisions:
>
> 1\) We are not completely convinced that paxillin functions as a \"molecular switch\" -- the authors do not perform experiments where they manipulate paxillin\'s binding state to endocytic or adhesion molecules and observe an ability to switch between neurite outgrowth/no outgrowth. Indeed, overexpression of CIP4 did not affect neural migration ([Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}) although the polarity of neurons was not quantified here. As part of the argument for the \"molecular switch\" model, the authors suggest that paxillin binds preferentially with endocytic factors when neurons are grown on soft cultures to initiate neurite outgrowth, whereas it binds preferentially with adhesion factors when neurons are grown on stiff cultures. This conclusion is drawn from colocalization in immunostaining in [Figures 3D-3F](#fig3){ref-type="fig"}, as well as co-IP in [Figure 4A](#fig4){ref-type="fig"}. However, the expression levels of endocytic and adhesion factors also change depending on the stiffness of the substrate -- could the increased localization of paxillin with vinculin and p-FAK on stiff substrates just reflect an increase in expression?

A\) In response to this comment, we have added genetic experiments that employ additional paxillin variants, namely, paxillin-∆LD1 and paxillin-∆LIM3-4, to manipulate paxillin binding affinity and assess effects on formation of proper neurite precursors. Based on domain mapping results shown in [Figure 4C](#fig4){ref-type="fig"} and revised [[Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}]{.ul}, we conclude that the paxillin-∆LD1 variant favors CIP4/clathrin association and that paxillin-∆LIM3-4 favors vinculin association. Using this approach, we found that ectopic expression of paxillin-∆LIM3-4 in 0.1 kPa cultures increased the neuritogenesis-delaying BL phenotype, whereas paxillin-∆LD1 expression reduced the size of the BL population in 20 kPa cultures. In contrast, ectopic expression of the paxillin LD 1-3 variant, which cannot bind vinculin or CIP4, had no significant effect on neurite outgrowth. These results demonstrate that manipulating paxillin's binding affinity to favor either endocytic or adhesion molecules can change the potential of newborn neurons to form proper neurites. These new data are now shown in the new [[Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}]{.ul}.

B\) We agree that greatly increased levels of adhesion factors may contribute to sequestering paxillin over less abundant endocytic factors on a stiff substrate. To minimize ambiguity, we now comment on this issue in the Discussion in reporting colocalization experiments (Please see Discussion, second paragraph). Overall, our findings support the idea that gene expression patterns and binding of accessory proteins, such as paxillin, that favor either endocytotic or adhesion reactions govern morphogenetic states of newly differentiated neurons following cell-matrix contact (for a schematic showing proposed model, please see [Figure 7H](#fig7){ref-type="fig"}).

3\) We thank the referee for thoughtful suggestions. We have now added quantitative measurements of polarity of in utero-electroporated (IUE) neurons to revised [Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}. Briefly, we categorized IUE neurons into three groups based on the number and morphology of neuronal processes: 1) polarized neurons -- cells bearing observable tailing processes (axons) and leading processes (dendrites); 2) unpolarized neurons -- cells bearing short neurites but lacking polarity; and 3) no-neurite neurons -- cells with no neurites. We observed no significant difference in the number of cells in each group between control and GFP-CIP4 overexpressing neurons. These new data are shown in the revised [Figure 5---figure supplement 2C](#fig5s2){ref-type="fig"}.

> 2\) Furthermore, is there evidence that such a substrate-based switch between neurite outgrowth and non-growth is physiologically relevant? Are there tissues in the developing brain or embryo with high enough stiffness to trigger the adhesion \"switch\" in paxillin (2016 AFM showed 400 Pa in retinotectal system)?

We thank the referees for this insightful question. We have now added comments relevant to this topic to the Discussion (please see Discussion, fourth paragraph). Based on studies reporting the natural stiffness of mouse embryonic cerebral cortex at E16.5 to E18.5 (Iwashita, M., et al., Development 2014), we surmise that a neuronal switch favoring paxillin/endocytic factor binding is required and activated immediately after embryonic neuronal differentiation to ensure timely neurite initiation. This switch may also promote departure of cells from neurogenic regions, such as the ventricular and subventricular zones, whose stiffness is relatively high compared to the cortical plate at E18.5. However, at a later developmental time-point (since brain stiffness increases with age) and at synaptic contact sites or neuromuscular junctions, the paxillin adhesion switch could take effect and regulate formation of contacts with postsynaptic cells or decrease the capacity for neurite outgrowth. For example, synapses at neuro-muscular junctions where repetitive muscle contraction can endow much greater localized stiffness than that seen in brain cortex may favor paxillin/adhesion machinery association. A paxillin-mediated switch from neuritogenesis to the development of cell adhesion could stabilize synapses and connectivity between pre-synaptic and post-synaptic cells.

> 3\) The evidence for vinculin vs. CIP4 competitive binding to paxillin could use more validation -- it appears that vinculin is capable of binding to the LD1 domain, and the authors find it necessary to use a highly truncated paxillin to disrupt binding of both vinculin and CIP4.

A\) We agree that the competition model needs support. Given that CIP4 forms a dimer in vitro and in vivo (as verified by small angle X-ray scattering analysis), we feel that increased CIP4 binding to paxillin LIM domains may spatially hinder vinculin from accessing the LD motifs. We investigated this possibility using two new sets of experiments. First, we conducted additional competition assays using paxillin variants, i.e., full-length paxillin, ∆LD1 paxillin, and ∆LIM3-4 domain. Overall, these studies showed that the presence of the vinculin-binding LD1 domain does not alter competition by CIP4 or vinculin for paxillin binding. In contrast, the CIP4-binding LIM 3-4 region is required for CIP4 competitive capacity, as CIP4 could not out-compete vinculin for binding to the paxillin-∆LIM3-4 construct. This new data is shown in [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}. Secondly, we undertook additional domain-mapping analyses using a series of N-terminal-truncated paxillin constructs (shown in [Figure 4](#fig4){ref-type="fig"} and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). These analyses showed that vinculin and CIP4 primarily associate with LD motifs (LD1, 2, and/or 4; Turner et al., J. Cell Biol., 1999) and the LIM domain, respectively. Nevertheless, we also noted that deletion of the paxillin LIM3-4 domain reduced its affinity for vinculin (see comparison of full-length paxillin versus paxillin-∆LIM3-4 constructs in [Figure 4C](#fig4){ref-type="fig"}), suggesting that the paxillin LIM3-4 domain is required for strong binding of vinculin to LD motifs. On the other hand, CIP4 shows detectable binding to the LD motif on the LD1-5 construct. These findings potentially explain why the CIP4-paxillin interaction interferes with the vinculin-LD association. Based on a previous report (Turner et al., J. Cell Biol., 1999) and our new results, we have revised the schematic model (shown in [Figure 4D](#fig4){ref-type="fig"}) and parts of the Results (subsection "Endocytic factor CIP4 and adhesion factor vinculin are potential competitors for paxillin binding", last paragraph) to avoid misinterpretation of the competitive-binding mechanism.

B\) We agree that vinculin and CIP4 interaction domains do not fully overlap on paxillin. Although the LIM-domain-truncated paxillin LD1-5 construct contains only vinculin-binding LD domains, it retains residual binding to CIP4. Therefore, we used the paxillin LD1-3 construct, which contains no LIM domain and lacks the last two LD domains, as the negative control. Also, we currently do not know if different forms of regulation, such as post-translational modification, govern paxillin binding preferences to CIP4 or vinculin in newborn neurons grown on different substrates.

> Minor points \[abridged\]:
>
> \[\...\] 8) Since this manuscript suggests that paxillin facilitates neurite growth by interacting with CIP4 and participating in endocytosis, it implies that CIP4 also has a positive role in neurite growth. However, a previous published paper (cited below) suggests that CIP4 inhibits neurite outgrowth, a conclusion that is opposite of this manuscript. All work done in the previous was performed on glass substrates. Is it possible that CIP4 also functions differently in substrates of different softness? Can the authors reconcile their conclusion with the previous study? \"The F-BAR Protein CIP4 Inhibits Neurite Formation by Producing Lamellipodial Protrusions\"Current Biology 22, 494-501, March 20, 2012.

We appreciate the referee pointing out that CIP4 may function differently on substrates of differing softness. We observed altered CIP4 distribution along the enlarged lamellar edge (as reported in Saengsawang et al., 2012), but only when CIP4-GFP-expressing neurons were cultured on 20 kPa gels or coverslips (states unfavorable for neurite initiation (see **[Figure 5-figure supplement 2B]{.ul}**). This altered CIP4 distribution may simply reflect CIP4\'s ability to bind lipid bi-layers where its accumulation may mark or reflect membrane curvature. In addition, we observed interactions of paxillin with CIP4 and endocytic machineries in neurons growing on a soft environment but not on coverslips, implying their function and associating complexes depend on cell content/state. Therefore, we feel that previous studies complement rather than challenge our findings. CIP4 over-expression also did not inhibit neurite formation in cortical progenitor cells or in neurons grown on soft substrates (0.1 kPa gels), conditions in which paxillin co-localizes with the endocytic machinery (please see **[Figures 3D, 3E, and Figure 5-figure supplement 2C]{.ul}**). Based on these results, we are confident that paxillin and CIP4 function in the endocytic machinery in newborn neurons grown in or on soft tissue environments.
